<SEC-DOCUMENT>0001193125-25-091456.txt : 20250423
<SEC-HEADER>0001193125-25-091456.hdr.sgml : 20250423
<ACCEPTANCE-DATETIME>20250423165646
ACCESSION NUMBER:		0001193125-25-091456
CONFORMED SUBMISSION TYPE:	S-3/A
PUBLIC DOCUMENT COUNT:		4
FILED AS OF DATE:		20250423
DATE AS OF CHANGE:		20250423

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			PLUS THERAPEUTICS, INC.
		CENTRAL INDEX KEY:			0001095981
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		ORGANIZATION NAME:           	08 Industrial Applications and Services
		EIN:				330827593
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		S-3/A
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-286393
		FILM NUMBER:		25862269

	BUSINESS ADDRESS:	
		STREET 1:		4200 MARATHON BLVD.
		STREET 2:		SUITE 200
		CITY:			AUSTIN
		STATE:			TX
		ZIP:			78756
		BUSINESS PHONE:		737.255.7194

	MAIL ADDRESS:	
		STREET 1:		4200 MARATHON BLVD.
		STREET 2:		SUITE 200
		CITY:			AUSTIN
		STATE:			TX
		ZIP:			78756

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CYTORI THERAPEUTICS, INC.
		DATE OF NAME CHANGE:	20050712

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	MACROPORE INC
		DATE OF NAME CHANGE:	20010320
</SEC-HEADER>
<DOCUMENT>
<TYPE>S-3/A
<SEQUENCE>1
<FILENAME>d930893ds3a.htm
<DESCRIPTION>S-3/A
<TEXT>
<HTML><HEAD>
<TITLE>S-3/A</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>As filed with the Securities and Exchange Commission on April&nbsp;23, 2025 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="right"><B>Registration <FONT STYLE="white-space:nowrap">No.&nbsp;333-286393</FONT> </B></P>
<P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;
</DIV><DIV STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV> <P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:17pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:17pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:17pt; font-family:Times New Roman" ALIGN="center"><B>WASHINGTON, D.C. 20549 </B></P>
<P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:17pt; font-family:Times New Roman" ALIGN="center"><B>AMENDMENT NO. 1 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:17pt; font-family:Times New Roman" ALIGN="center"><B>TO
</B></P>  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:17pt; font-family:Times New Roman" ALIGN="center"><B>FORM <FONT STYLE="white-space:nowrap">S-3</FONT> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:17pt; font-family:Times New Roman" ALIGN="center"><B>REGISTRATION STATEMENT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B><I>UNDER </I></B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B><I>THE
SECURITIES ACT OF 1933 </I></B></P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>PLUS THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Exact name of registrant as specified in its charter) </B></P>
<P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:7.5pt" ALIGN="center">


<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"><B>Delaware</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">33-0827593</FONT></B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7.5pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7.5pt; font-family:Times New Roman" ALIGN="center"><B>(State or other jurisdiction of</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:7.5pt; font-family:Times New Roman" ALIGN="center"><B>incorporation or organization)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7.5pt; font-family:Times New Roman" ALIGN="center"><B>(I.R.S. Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:7.5pt; font-family:Times New Roman" ALIGN="center"><B>Identification Number)</B></P></TD></TR>
</TABLE> <P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>2710 Reed Road, Suite 160 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Houston,&nbsp;Texas&nbsp;77051 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(737) <FONT STYLE="white-space:nowrap">255-7194</FONT> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7.5pt; font-family:Times New Roman" ALIGN="center"><B>(Address, including zip code, and telephone number, including area code, of registrant&#146;s principal executive offices) </B></P>
<P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Marc H. Hedrick, M.D. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>President and Chief Executive Officer </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Plus Therapeutics, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>2710 Reed Road, Suite 160 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Houston,&nbsp;Texas&nbsp;77051 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(737) <FONT STYLE="white-space:nowrap">255-7194</FONT> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7.5pt; font-family:Times New Roman" ALIGN="center"><B>(Name, address, including zip code, and telephone number, including area code, of agent for service) </B></P>
<P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B><I>Copies to: </I></B></P> <P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Andrew
L. Strong </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>William I. Intner </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Hogan Lovells US LLP </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>609
Main Street, Suite 4200 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Houston,&nbsp;Texas&nbsp;77002 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(713) <FONT STYLE="white-space:nowrap">632-1400</FONT> </B></P>
<P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><B>Approximate Date of Commencement of Proposed Sale to the Public: </B>From time to time after the effective date of this registration statement. </P>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">If the only securities being registered on this Form are being offered pursuant to dividend or interest reinvestment plans, please check the following
box:&#8194;&#9744; </P> <P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the
Securities Act of 1933, other than securities offered only in connection with dividend or interest reinvestment plans, check the following box:&#8194;&#9746; </P>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and
list the Securities Act registration statement number of the earlier effective registration statement for the same offering.&#8194;&#9744; </P> <P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">If this Form is
a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.&#8194;&#9744;
</P> <P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">If this Form is a registration statement pursuant to General Instruction I.D. or a post-effective amendment thereto that shall become effective upon filing
with the Commission pursuant to&nbsp;Rule 462(e) under the Securities Act, check the following box.&#8194;&#9744; </P> <P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">If this Form is a post-effective
amendment to a registration statement filed pursuant to General Instruction I.D. filed to register additional securities or additional classes of securities pursuant to&nbsp;Rule 413(b) under the&nbsp;Securities Act, check the following
box.&#8194;&#9744; </P> <P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a
<FONT STYLE="white-space:nowrap">non-accelerated</FONT> filer, smaller reporting company, or an emerging growth company. See the definitions of &#147;large accelerated filer,&#148; &#147;accelerated filer,&#148; &#147;smaller reporting
company,&#148; and &#147;emerging growth company&#148; in Rule <FONT STYLE="white-space:nowrap">12b-2</FONT> of the Exchange Act. </P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="13%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="66%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="17%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="1%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">Large&nbsp;accelerated&nbsp;filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9744;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Accelerated&nbsp;filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9744;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">Non-accelerated filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9746;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Smaller&nbsp;reporting&nbsp;company</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9746;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Emerging&nbsp;growth&nbsp;company</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9744;</TD></TR>
</TABLE> <P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting standards provided pursuant to Section&nbsp;7(a)(2)(B) of the Securities Act.&#8194;&#9744; </P>
<P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><B>The registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the registrant shall
file a further amendment that specifically states that this registration statement shall thereafter become effective in accordance with Section&nbsp;8(a) of the Securities Act or until the registration statement shall become effective on such date
as the Securities and Exchange Commission, acting pursuant to said Section&nbsp;8(a), may determine. </B></P>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;
</DIV><DIV STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <DIV STYLE="position:relative; overflow:visible; width:651pt; height:30pt; transform-origin:bottom left; transform: rotate(-90deg) translate(-100%, 100%) translateX(30pt);">
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Arial Narrow"><FONT COLOR="#ff4338"><B>The information in this preliminary prospectus is not complete and may be changed. These securities may not be sold until the
registration statement filed with the Securities and Exchange Commission is effective. This preliminary prospectus is not an offer to sell nor the solicitation of an offer to buy these securities in any jurisdiction where the offer or sale is not
permitted. </B></FONT></P></DIV><DIV STYLE="position:relative; overflow:visible; margin-left:48pt; margin-right:48pt; transform: translateY(-30pt);"> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#ff4338"><B>SUBJECT TO COMPLETION DATED APRIL&nbsp;23, 2025 </B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><B>PRELIMINARY PROSPECTUS </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g930893g25p25.jpg" ALT="LOGO" STYLE="width:2.52161in;height:0.877083in;">
 </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:13pt; font-family:Times New Roman" ALIGN="center"><B>Up to 1,565,044,860 Shares of Common Stock </B></P>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">This prospectus relates to up to an aggregate of 1,565,044,860 shares of common stock, par value $0.001, of Plus Therapeutics, Inc., a Delaware corporation
(&#147;Plus Therapeutics,&#148; &#147;Company,&#148; &#147;we,&#148; &#147;us&#148; or &#147;our&#148;), which may be offered for sale from time to time by selling stockholders named herein. The shares of common stock covered in this prospectus
consist of: </P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:8pt">up to 3,077,270 shares of common stock; </P></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:8pt">up to 19,650,000 shares of common stock issuable upon exercise of
<FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants <FONT STYLE="white-space:nowrap">(&#147;Pre-Funded</FONT> Warrants&#148;); </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:8pt">up to 280,421,380 shares of common stock that as a result of certain adjustment provisions set forth in the Series
A common stock warrants (&#147;Series A Common Stock Warrants&#148;) and assumptions described elsewhere in this prospectus could become issuable upon exercise of Series A Common Stock Warrants; and </P></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:8pt">up to 1,261,896,210 shares of common stock that as a result of certain adjustment provisions set forth in the
Series&nbsp;B common stock warrants (&#147;Series B Common Stock Warrants&#148;, and together with the Series A Common Stock Warrants, the &#147;Common Warrants&#148;) and assumptions described elsewhere in this prospectus could become issuable upon
exercise of Series B Common Stock Warrants. </P></TD></TR></TABLE> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">The shares of common stock, <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants and
Common Warrants were issued pursuant to the Securities Purchase Agreement, dated March&nbsp;4, 2025 (the &#147;Purchase Agreement&#148;), among us and certain accredited investors (the &#147;Purchasers,&#148; or &#147;selling stockholders&#148;).
</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">The shares of common stock are registrable for resale pursuant to the Registration Rights Agreement, dated March&nbsp;4, 2025 (the &#147;Registration
Rights Agreement&#148;), that we entered into with the Purchasers in connection with the Purchase Agreement. See the section entitled &#147;Selling Stockholders&#148; for additional information regarding the Purchasers. Our registration of the
resale of the shares of common stock covered by this prospectus does not mean that the selling stockholders will offer or sell all or any of the shares of common stock. The selling stockholders may offer, sell or distribute all or portion of their
shares of common stock from time to time directly or indirectly through one or more underwriters, broker-dealers or agents, and in one or more public or private transactions. The shares of common stock may be sold in one or more transactions at
fixed prices, at prevailing market prices at the time of the sale, at varying prices determined at the time of sale or at negotiated prices. These sales may be effected in transactions, which may involve crosses or block transactions. See the
section entitled &#147;Plan of Distribution&#148; for more information. </P>  <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">We are not selling any shares of common stock under this prospectus and will
not receive any proceeds from the sale of shares of common stock by the selling stockholders or their donees, pledgees, assignees, transferees or other
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">successors-in-interest,</FONT></FONT> except with respect to amounts received by us upon exercise of the <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants, the Series A
Common Stock Warrants and the Series B Common Stock Warrants (collectively, the &#147;Warrants&#148;), to the extent the Warrants are exercised for cash. The Series B Common Stock Warrants are exercisable for cash or pursuant to a zero exercise
price provision, pursuant to which the Series B Common Stock Warrants can be exercised without further payment to us and for three times the number of shares of common stock issuable upon exercise of the Series B Common Stock Warrants for cash. As a
result, we do not expect to receive any cash proceeds from the exercise of the Series B Common Stock Warrants because it is highly unlikely that a warrant holder would exercise their Series B Common Stock Warrants for cash rather than pursuant to
the zero exercise price provision. </P>  <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">We will bear the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT>
costs, expenses, and fees incurred in connection with the registration of the shares of common stock to be sold by the selling stockholders pursuant to this prospectus. Other than registration-related expenses, the selling stockholders will bear
their own broker or similar commissions payable with respect to any sales of their shares of common stock and any legal fees or other costs of the selling stockholders related thereto. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">As of March 21, 2025, we had 16,999,626 shares of common stock issued and outstanding. We are registering for resale an aggregate of 1,565,044,860 shares of our
common stock, which represents approximately 9,206% of the 16,999,626 shares of our common stock outstanding, and approximately 99% of our total shares of common stock outstanding assuming the exercise of all of the Warrants and issuance of the
maximum number of shares of common stock that may be issuable upon exercise of the Warrants. Sales of a substantial number of shares of our common stock by the selling stockholders in the public market could occur at any time. Whether as a result of
sales of a substantial number our shares of our common stock by the selling stockholders or the perception that such sales may occur, the market price of shares of our common stock could decline significantly and the volatility of the market price
of our shares of common stock could increase significantly.&nbsp;See <I>&#147;Risk Factors&#148;</I>&nbsp;beginning on page 3 of this prospectus for more information. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">Our common stock is listed on The Nasdaq Capital Market (&#147;Nasdaq&#148;) under the trading symbol &#147;PSTV.&#148; On April 21, 2025, the closing sale
price of our common stock was $0.641 per share. </P>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:Times New Roman"><B>Investing in our shares of common stock involves a high degree of risk that are described in the section entitled &#147;</B><B><I><A HREF="#toc930893_6">Risk
 Factors</A></I></B><B>&#148; beginning on page 3 of this prospectus and under similar headings in the documents incorporated by reference into this prospectus. You should also review carefully any risk factors included in any applicable prospectus
supplement for a discussion of additional risks that you should consider before investing in our common stock. </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><B>Neither the Securities and Exchange
Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense. </B></P>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>The date of this prospectus is&#8195;&#8195;&#8195;&#8195;, 2025. </B></P></DIV> <p STYLE="clear:both; font-size:1pt; height:0">&nbsp;</p>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc"></A>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="97%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><A HREF="#toc930893_1">ABOUT THIS PROSPECTUS </A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>ii</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><A HREF="#toc930893_2">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</A></B></P></TD>

<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>iii</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><A HREF="#toc930893_3">PROSPECTUS SUMMARY </A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>1</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><A HREF="#toc930893_4">OUR COMPANY</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>1</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><A HREF="#toc930893_5">THE OFFERING</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>2</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><A HREF="#toc930893_6">RISK FACTORS</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>3</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><A HREF="#toc930893_7">USE OF PROCEEDS</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>5</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><A HREF="#toc930893_8">SELLING STOCKHOLDERS </A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>8</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><A HREF="#toc930893_9">PLAN OF DISTRIBUTION </A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>13</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><A HREF="#toc930893_10">LEGAL MATTERS</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>16</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><A HREF="#toc930893_11">EXPERTS</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>16</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><A HREF="#toc930893_12">WHERE YOU CAN FIND ADDITIONAL INFORMATION </A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>16</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><A HREF="#toc930893_13">INFORMATION INCORPORATED BY REFERENCE</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>16</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
</TABLE>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>You should rely only on the information provided in this prospectus, as well as the information incorporated by reference to exhibits to the registration
statement of which this prospectus forms a part and any applicable prospectus supplement or amendment. Neither we nor the selling stockholders have authorized anyone to provide you with different information. Neither we nor the selling stockholders
are making an offer of these securities in any jurisdiction where the offer is not permitted. You should not assume that the information in this prospectus or any applicable prospectus supplement is accurate as of any date other than the date of the
applicable document. Since the date of this prospectus and the documents filed as exhibits to the registration statement of which this prospectus forms a part, our business, financial condition, results of operations and prospects may have
changed.</B> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">i </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc930893_1"></A>ABOUT THIS PROSPECTUS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus is part of a registration statement that we filed with the Securities and Exchange Commission (the &#147;SEC&#148;) using a &#147;shelf&#148;
registration process. Under this shelf registration process, the selling stockholders identified in this prospectus under the section entitled &#147;Selling Stockholders,&#148; may use the shelf registration statement to offer and resell, from time
to time, up to an aggregate of 1,565,044,860 shares of our common stock through any means described in the section entitled &#147;Plan of Distribution&#148;. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A prospectus supplement may also add, update or change information included in this prospectus. Any statement contained in this prospectus will be deemed to
be modified or superseded for purposes of this prospectus to the extent that a statement contained in such prospectus supplement modifies or supersedes such statement. Any statement so modified will be deemed to constitute a part of this prospectus
only as so modified, and any statement so superseded will be deemed not to constitute a part of this prospectus. You should rely only on the information contained in this prospectus, any applicable prospectus supplement or any related free writing
prospectus, including any information incorporated by reference. See &#147;<I>Where You Can Find More Information</I>&#148; and &#147;<I>Information Incorporated by Reference</I>.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are not selling any shares of common stock under this prospectus, and we will not receive any proceeds from the sale of shares of common stock offered
hereby by the selling stockholders, although we may receive cash from the exercise of the Warrants (as defined in this prospectus). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You should rely only
on the information provided in this prospectus, including any information incorporated by reference. We have not authorized anyone to provide you with any other information and we take no responsibility for, and can provide no assurances as to the
reliability of, any other information that others may give you. The information contained in this prospectus speaks only as of the date set forth on the cover page and may not reflect subsequent changes in our business, financial condition, results
of operations and prospects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Neither we nor the selling stockholders have authorized anyone to provide any information or to make any representations
other than those contained in this prospectus, any accompanying prospectus supplement or any free writing prospectus we have prepared. We and the selling stockholders take no responsibility for, and can provide no assurance as to the reliability of,
any other information that others may give you. This prospectus is an offer to sell only the shares of common stock offered hereby and only under circumstances and in jurisdictions where it is lawful to do so. No dealer, salesperson or other person
is authorized to give any information or to represent anything not contained in this prospectus, any applicable prospectus supplement or any related free writing prospectus. This prospectus is not an offer to sell securities, and it is not
soliciting an offer to buy securities, in any jurisdiction where the offer or sale is not permitted. You should assume that the information appearing in this prospectus or any prospectus supplement is accurate only as of the date of those documents
and that any information incorporated by reference is accurate only as of the date of the document incorporated by reference (or, in each case, any earlier date specified for such information, unless we indicate otherwise), regardless of the time of
delivery of this prospectus or any applicable prospectus supplement, or any sale of a security. Our business, financial condition, results of operations and prospects may have changed since those dates. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ii </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc930893_2"></A>CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus contains &#147;forward-looking statements&#148; for purposes of the federal securities laws. In addition, any statements that refer to
projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. Words such as &#147;anticipate,&#148; &#147;believe,&#148; &#147;can,&#148;
&#147;continue,&#148; &#147;could,&#148; &#147;designed,&#148; &#147;estimate,&#148; &#147;expect,&#148; &#147;intend,&#148; &#147;likely,&#148; &#147;may,&#148; &#147;might,&#148; &#147;plan,&#148; &#147;possible,&#148; &#147;potential,&#148;
&#147;predict,&#148; &#147;project,&#148; &#147;seek,&#148; &#147;should,&#148; &#147;target,&#148; &#147;will&#148; and &#147;would,&#148; as well as similar expressions which predict or indicate future events and trends or which do not relate to
historical matters, are intended to identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. For example, we may use forward-looking statements when addressing topics such as: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our anticipated expenditures, including research and development, and general and administrative expenses;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to enter into strategic arrangements and/or collaborations and to realize the potential benefits of
such arrangements, including license agreements; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">U.S. Food and Drug Administration and European Medicines Agency approvals and interactions and government
regulation; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the potential size of the market for our product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing or likelihood of regulatory filings and our ability to obtain and maintain regulatory approvals;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any future commercialization of our product candidates and laboratory tests; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to enroll patients in our clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability and the potential to successfully manufacture and supply our product candidates or laboratory tests
for clinical trials and for commercial use; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our estimates regarding the potential market size and market opportunity for our product candidates and
laboratory tests; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our research and development efforts; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing of the initiation, progress, and expected results of our nonclinical studies, our <FONT
STYLE="white-space:nowrap">pre-clinical</FONT> and clinical trials, and our research and development programs; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to advance product candidates into, and successfully complete, nonclinical studies and clinical
trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">results from our <FONT STYLE="white-space:nowrap">pre-clinical</FONT> and clinical studies and the implications
of such results regarding the efficacy or safety of our product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the safety profile, pathways, and efficacy of our product candidates and formulations; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the anticipated advantages of our product candidates and laboratory tests over other products available in the
market and being developed; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the populations that will most benefit from our product candidates and indications that will be pursued with each
product candidate; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the anticipated progress in our current and future clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">plans and strategies to create novel technologies; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the scope of protection we are able to establish and maintain for intellectual property rights covering our
technology platforms and product candidates, and the defense of such intellectual property rights; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">iii </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">developments relating to our competitors and our industry, including competing product candidates, therapies and
laboratory tests; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">future development and/or expansion of our product candidates, therapies and laboratory tests in our markets;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">sources of competition for any of our product candidates or laboratory tests; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to generate revenue and the sources of such revenue; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to effectively manage our gross profit margins; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our potential need for additional financing and the availability thereof; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to continue as a going concern; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to remain listed on Nasdaq; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our estimates regarding expenses, capital requirements, and needs for additional financing and our ability to
obtain additional capital; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to repay or refinance some or all of our outstanding indebtedness and our ability to raise capital in
the future; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to integrate into our business and operations, develop, fully utilize and monetize acquired assets;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to transfer the drug product manufacturing to a contract drug manufacturing organization;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the potential enhancement of our cash position through development, marketing, and licensing arrangements;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the implementation of our business model, strategic plans for our business, and product candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to contract with third-party suppliers and manufacturers and their ability to perform adequately;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to prevent or timely detect a material security breach or cyber security attack affecting our
operations and property; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our use of the proceeds from any exercise of the Warrants; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">other factors detailed under the section entitled &#147;<I>Risk Factors</I>&#148; in this prospectus.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have based these forward-looking statements largely on our current expectations and projections about future events and financial
trends that we believe may affect our business, financial condition and results of operations. Forward-looking statements are not guarantees of future performance, conditions or results, and are subject to risks, uncertainties and assumptions that
are difficult to predict. Therefore, actual results may differ materially and adversely from those anticipated in any forward-looking statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as
of the date of this prospectus. While we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive
inquiry into, or review of, all potentially available relevant information. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We undertake no obligation to update or revise any forward-looking statements
contained in this prospectus, whether as a result of new information, future events or otherwise. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">iv </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc930893_3"></A>PROSPECTUS SUMMARY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>This summary highlights selected information from this prospectus and may not contain all of the information that is important to you in making your
investment decision. Before investing in our shares of common stock, you should carefully read the entire prospectus, including the information set forth under the heading &#147;Risk Factors&#148; and the financial statements and related notes and
other information that we incorporate by reference herein, including our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> and our Quarterly Reports on Form <FONT STYLE="white-space:nowrap">10-Q.</FONT> See also the sections
entitled &#147;Where You Can Find Additional Information&#148; and &#147;Incorporation by Reference.&#148; Unless the context indicates otherwise, references in this prospectus to &#147;Plus Therapeutics,&#148; &#147;we,&#148; &#147;our&#148; and
&#147;us&#148; refer, collectively, to Plus Therapeutics, Inc., a Delaware corporation, and its subsidiary taken as a whole. </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc930893_4"></A>Our Company </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Plus Therapeutics is a
U.S. pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (&#147;CNS&#148;) cancers. Our novel radioactive drug formulations, medical devices and therapeutic candidates are
designed to deliver safe and effective doses of radiation to tumors. To achieve this, we have developed innovative approaches to drug formulation, including encapsulating radionuclides such as rhenium isotopes with nanoliposomes and microspheres.
Our formulations are intended to achieve elevated patient-absorbed radiation doses and extend retention times such that the clearance of the isotope occurs after significant and essentially complete radiation decay, which will contribute and provide
less normal tissue/organ exposure and improved safety margins. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our lead radiotherapeutic candidate,
REYOBIQ<SUP STYLE="font-size:75%; vertical-align:top">&#153;</SUP> (rhenium (186Re) obisbemeda), is designed specifically for CNS cancers including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers by direct localized
delivery utilizing approved <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">standard-of-care</FONT></FONT> tissue access such as with convection-enhanced delivery and intraventricular brain (Ommaya reservoir) catheters. Our
acquired radiotherapeutic candidate, <FONT STYLE="white-space:nowrap">Rhenium-188</FONT> NanoLiposome Biodegradable Alginate Microsphere is designed to treat many solid organ cancers including primary and secondary liver cancers by intra-arterial
injection. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On April&nbsp;26, 2024, we acquired the cerebrospinal fluid cancer diagnostic portfolio known as the &#147;CNSide<SUP
STYLE="font-size:75%; vertical-align:top">&reg;</SUP> Platform&#148; that is currently being utilized in the <FONT STYLE="white-space:nowrap">ReSPECT-LM</FONT> clinical trial funded by the Cancer Prevention and Research Institute of Texas. We are
planning for the CNSide Cerebrospinal Fluid Tumor Cell Enumeration test, which is a laboratory developed test, to be <FONT STYLE="white-space:nowrap">re-introduced</FONT> to the U.S. market starting in the second quarter of 2025 after we complete a
number of steps related to certifications, state licensure, payor coverages, reimbursement codes and financing. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Company Information </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In March 2025, we moved our headquarters to Houston, Texas, in proximity to world-class cancer institutions and researchers. Our principal executive offices
are located at 2710 Reed Road, Suite 160, Houston, Texas 77051, and our telephone number is (737) <FONT STYLE="white-space:nowrap">255-7194.</FONT> We maintain a website at www.plustherapeutics.com. We make available free of charge through our
website our Annual Reports on Form <FONT STYLE="white-space:nowrap">10-K,</FONT> Quarterly Reports on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> and Current Reports on Form <FONT STYLE="white-space:nowrap">8-K,</FONT> and amendments to these
reports filed or furnished pursuant to Section&nbsp;13(a) or 15(d) of the Securities Exchange Act of 1934, as amended (the &#147;Exchange Act&#148;), as soon as reasonably practicable after we electronically file such material with, or furnish such
material to, the SEC. These reports and other information are also available, free of charge, at www.sec.gov. Information contained on, or that can be accessed through, the websites referenced in this prospectus are not a part of, or incorporated by
reference into, this prospectus. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc930893_5"></A>The Offering </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Issuer </P></TD>
<TD>Plus Therapeutics, Inc. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Common stock offered by the Selling Stockholders </P></TD>
<TD>Up to 1,565,044,860 shares of common stock, including (i)&nbsp;3,077,270 shares of common stock, (ii)&nbsp;19,650,000 shares of common stock issuable upon exercise of <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants,
(iii)&nbsp;280,421,380 shares of common stock that could become issuable upon exercise of Series A Common Stock Warrants, (iv)&nbsp;1,261,896,210 shares of common stock that could become issuable upon exercise of Series B Common Stock Warrants,
which we issued in a private placement transaction (the &#147;March PIPE Financing&#148;) pursuant to the Purchase Agreement, among us and the Purchasers. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Use of proceeds </P></TD>
<TD>We are not selling any securities under this prospectus and will not receive any proceeds from the sale of the shares of common stock by the selling stockholders covered by this prospectus. We may, however, receive up to approximately
$37&nbsp;million in aggregate gross proceeds from the exercise of the <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants and the Series A Common Warrants if such warrants are exercised for cash. The Series B Common Stock Warrants are
exercisable for cash, in which case we could receive up to approximately $55.5 million in aggregate gross proceeds, or pursuant to a zero exercise price provision, pursuant to which the Series B Common Stock Warrants can be exercised without further
payment to us and for three times the number of shares of common stock issuable upon exercise of the Series B Common Stock Warrants for cash. We believe it is highly unlikely that a warrant holder would exercise their Series B Common Stock Warrants
for cash rather than pursuant to the zero exercise price provision. To the extent that we receive any proceeds from the exercise of the Warrants, we intend to use the proceeds for general corporate purposes. See the section titled &#147;Use of
Proceeds.&#148; </TD></TR></TABLE>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Nasdaq Symbol </P></TD>
<TD>&#147;PSTV&#148; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Offering price </P></TD>
<TD>The selling stockholders will offer the shares of common stock offered by this prospectus at fixed prices, at prevailing market prices at the time of the sale, at varying prices determined at the time of sale or at negotiated prices.
</TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Risk factors </P></TD>
<TD>Any investment in our shares of common stock offered hereby is speculative and involves a high degree of risk. You should carefully consider the information set forth under the section entitled &#147;<I>Risk Factors</I>&#148; and elsewhere in
this prospectus. </TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc930893_6"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">An investment in our shares of common stock involves a high degree of risk. In addition to the risks and uncertainties discussed below, and above under
&#147;Cautionary Note Regarding Forward-Looking Statements,&#148; you should carefully consider the risk factors incorporated by reference to our most recent Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> and all other
information contained or incorporated by reference into this prospectus, as updated by our subsequent filings under the Exchange Act, and the risk factors and other information contained in any applicable prospectus supplement, before making an
investment decision. Our business, prospects, financial condition or operating results could decline due to any of these risks and, as a result, you may lose all or part of your investment. The occurrence of any of these risks might cause you to
lose all or part of your investment in the offered securities. We may face additional risks and uncertainties that are not presently known to us, or that we currently deem immaterial. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We are registering for resale an aggregate of 1,565,044,860 shares of common stock, including an aggregate of 1,542,317,700 shares of common stock
issuable upon exercise of the Warrants, and the issuance and sale of these shares (or the perception that such sales may occur) may depress the market price of our common stock and cause immediate and substantial dilution to our existing
stockholders. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of March 21, 2025, we had 16,999,626 shares of common stock issued and outstanding. We are registering for resale an aggregate of
1,565,044,860 shares of our common stock, which represents approximately 9,206% of the 16,999,626 shares of our common stock outstanding and approximately 99% of our total shares of common stock outstanding assuming the exercise of all of the
Warrants and issuance of the maximum number of shares of common stock that may be issuable upon exercise of the Warrants. The Series B Common Stock Warrants are subject to a zero exercise price provision, pursuant to which the Series B Common Stock
Warrants can be exercised without further payment to us and for three times the number of shares of common stock issuable upon exercise of the Series B Common Stock Warrants for cash. The Common Warrants include a reset provision described below
under &#147;Private Placement,&#148; pursuant to which the exercise price of the Common Warrants may be reduced to a price not lower than $0.132 (the &#147;Floor Price&#148;). On April 21, 2025, the closing sale price of our common stock was $0.641
per share. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the exercise price of the Series A Common Stock Warrants is reduced to the Floor Price pursuant to the reset provision, the 28,042,138
outstanding Series A Common Stock Warrants would become exercisable for an aggregate of up to 280,421,380 shares of common stock. The 28,042,138 outstanding Series&nbsp;B Common Stock Warrants would be exercisable for an aggregate of up to
84,126,414 shares of common stock assuming the Series B Common Stock Warrants are exercised pursuant to the zero exercise price provision. In the event that the exercise price of the Series B Common Stock Warrants is reduced to the Floor Price
pursuant to the reset provision, the Series B Common Stock Warrants would become exercisable for an aggregate of up to 420,632,070 shares of common stock, or an aggregate of up to 1,261,896,210 shares of common stock assuming the Series B Common
Stock Warrants are exercised pursuant to the zero exercise price provision. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any sale of such shares may depress the market price of our common stock.
Sales of a substantial number of shares of our common stock by the selling stockholders in the public market could occur at any time. Whether as a result of sales of a substantial number of shares of our common stock by the selling stockholders or
the perception that such sales may occur, the market price of shares of our common stock could decline significantly and the volatility of the market price of our shares of common stock could increase significantly. In addition, the issuance of
shares upon exercise of the Warrants will cause immediate and substantial dilution to our stockholders. For example, if the maximum aggregate of 1,542,317,700 shares of common stock issuable upon exercise of the Warrants were issued, the ownership
interest of our existing stockholders, other than the holders of the Warrants whose ownership interests would materially increase, would be correspondingly diluted by approximately 99%. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The price of our common stock may decline or be depressed as a result of short sales. There is an
increased potential for short sales of our common stock due to the sale of shares of our common stock pursuant to the Purchase Agreement, which could materially and adversely affect the market price of our common stock. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">When an investor sells stock that it does not own, it is known as a short sale. The short selling investor, anticipating that the price of the stock will go
down, intends to buy stock to cover its sale at a later date. If the price of the stock goes down, the short selling investor will profit to the extent of the difference between the price at which it originally sold it less its later purchase price.
The Purchase Agreement does not contain a prohibition against short sales by the selling stockholders, including between the date that the March PIPE Financing was consummated and the date that the Warrant Stockholder Approval (as defined below) is
obtained, if at all. As such, receipt of the Warrant Stockholder Approval and, in particular the large number of shares of common stock then issuable upon exercise of the Common Warrants and the exercise price adjustment provisions in the Common
Warrants, could encourage&nbsp;short&nbsp;sales&nbsp;of our common stock by the selling stockholders. When and if the Warrant Stockholder Approval is obtained, significant amounts of such short selling could place further downward pressure on the
market price of our common stock. Any significant downward pressure on the price of our common stock as the selling stockholders sell their shares of our common stock could encourage other stockholders to sell as well as short sales by the selling
stockholders or others. Any such short sales could place further downward pressure on the price of our common stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>There is no assurance that we
will be able to continue to comply with Nasdaq&#146;s minimum bid price requirement, and as a result our common stock may become delisted, which could have a material adverse effect on the liquidity of our common stock and our ability to raise
capital. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To maintain the listing of our shares of common stock on the Nasdaq, our common stock must maintain a minimum bid price of $1.00 as set
forth in Nasdaq Rule 5550(a)(2). If the closing bid price of our common stock is below $1.00 for 30 consecutive trading days, Nasdaq will send a deficiency notice to us, advising us that we have been afforded a &#147;compliance period&#148; of 180
calendar days to regain compliance with the applicable requirements. The closing&nbsp;bid price&nbsp;for our common stock fell below the minimum&nbsp;$1.00 per share&nbsp;required for continued listing on Nasdaq pursuant to Rule 5550(a)(2), starting
on April 2, 2025. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There is no assurance that we will be able to meet Nasdaq&#146;s listing requirements or comply with the requisite Nasdaq requirements
to maintain our listing of common stock on Nasdaq. If Nasdaq delists our securities from trading on its exchange and we are not able to list our securities on Nasdaq or any other national securities exchange, we could face significant material
adverse consequences, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a limited availability of market quotations for our common stock; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reduced liquidity for our common stock; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a determination that our common stock is a &#147;penny stock,&#148; which will require brokers trading in our
common stock to adhere to more stringent rules and possibly result in a reduced level of trading activity in the secondary trading market for our securities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a limited amount of news and analyst coverage for us; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a decreased ability to issue additional securities or obtain additional financing in the future; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the incurring of additional costs under state blue sky laws in connection with any sales of our securities.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If our common stock is delisted by Nasdaq, our common stock may be eligible to trade on an over-the-counter quotation system where an
investor may find it more difficult to sell our stock or obtain accurate quotations as to the market value of our common stock. In the event our common stock is delisted from Nasdaq, we may not be able to list our common stock on another national
securities exchange or obtain quotation on an over-the-counter quotation system. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Furthermore, any efforts we take to maintain our listing
on Nasdaq, including pursuing a reverse stock split, may not be sufficient. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc930893_7"></A>USE OF PROCEEDS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We will not receive any proceeds from any sale of shares of our common stock by the selling stockholders or their permitted transferees. All proceeds from the
sale of shares of common stock will be for the accounts of the selling stockholders or their permitted transferees. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We will only receive net proceeds to
the extent that the Warrants are exercised for cash. We expect to use any such net proceeds from the exercise of the Warrants for general corporate purposes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our expected use of proceeds described above represents our current intentions based on our present plans and business condition. The amounts and timing of
our actual expenditures will depend on numerous factors, including the time and cost necessary to conduct our planned clinical trials, the results of our planned clinical trials, and other factors described in &#147;<I>Risk Factors</I>&#148; in this
prospectus, as well as the amount of cash used in our operations and any unforeseen cash needs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We will bear the <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> costs, expenses, and fees incurred in connection with the registration of the shares of common stock to be sold by the selling stockholders pursuant to this prospectus. Other than
registration-related expenses, the selling stockholders will bear their own broker or similar commissions payable with respect to any sales of their shares of common stock and any legal fees or other costs of the selling stockholders related
thereto. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PRIVATE PLACEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The shares of common stock, <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants and Common Warrants being registered hereunder were issued in the
March PIPE Financing pursuant to the Purchase Agreement, among us and the Purchasers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Exercise Price</I>. The exercise price of each Prefunded Warrant
is $0.001 per share of common stock. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The initial exercise price of each Series&nbsp;A Common Stock Warrant is $1.32 per share of common stock,
subject to the &#147;reset&#148; provision described below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The initial exercise price of each Series&nbsp;B Common Stock Warrant is $1.98 per share of
common stock, subject to the &#147;reset&#148; provision described below, or pursuant to a zero exercise price option, which is referred to in the Series B Warrant as an &#147;alternative cashless exercise.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Reset Provision. </I>The exercise price of the Common Warrants will reset to a price equal to the greater of (i) the Floor Price, and (ii)&nbsp;the lowest
volume weighted average price during the period commencing on the first trading day immediately following the later of (x)&nbsp;the earlier of (A)&nbsp;the first (1<SUP STYLE="font-size:75%; vertical-align:top">st</SUP>) trading day after the
registration statement of which this prospectus forms a part is declared effective, or (B)&nbsp;the first (1<SUP STYLE="font-size:75%; vertical-align:top">st</SUP>) trading day after the date on which the holder of those securities can sell them
pursuant to Rule&nbsp;144 without restriction or limitation, or (y)&nbsp;the first (1<SUP STYLE="font-size:75%; vertical-align:top">st</SUP>) trading day after the Warrant Stockholder Approval is obtained, and the number of shares issuable upon
exercise will be proportionately adjusted such that the aggregate exercise price will remain unchanged. The Floor Price is subject to appropriate adjustment for any stock dividend, stock split, stock combination, reclassification or similar
transaction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The number of shares issuable upon exercise of the Common Warrants will increase in proportion to the amount by which the exercise price is
reduced below the initial exercise price of the applicable Common Warrant. In the event that the exercise price of the Series A Common Stock Warrants is reduced to the Floor Price pursuant to the reset provision, the 28,042,138 outstanding Series A
Common Stock Warrants would become exercisable for an aggregate of up to 280,421,380 shares of common stock at the Floor Price. The 28,042,138 outstanding Series&nbsp;B Common Stock Warrants would be exercisable for an aggregate of up to 84,126,414
shares of common stock assuming the Series B Common Stock Warrants are exercised pursuant to the zero exercise price provision. In the event that the exercise price of the Series B Common Stock Warrants is reduced to the Floor Price pursuant to the
reset provision, the Series B Common Stock Warrants would become exercisable for an aggregate of up to 420,632,070 shares of common stock, or an aggregate of up to 1,261,896,210 shares of common stock assuming the Series B Common Stock Warrants are
exercised pursuant to the zero exercise price provision. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Adjustment for Subsequent Issuances</I>. Subject to certain exceptions, if the Company sells
any common stock (or securities convertible into or exercisable into common stock) at a price per share (or conversion or exercise price, as applicable) less than the exercise price of the Series&nbsp;A Common Stock Warrants then in effect, then the
exercise price of the Series&nbsp;A Common Stock Warrants will be reduced to such lower price, but no lower than the Floor Price, and the number of shares issuable upon exercise will be proportionately adjusted such that the aggregate exercise price
will remain unchanged. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Share Combination Event Adjustment</I>. If at any time on or after the date of issuance there occurs any share split,
share dividend, share combination recapitalization or other similar transaction involving our common stock and the lowest daily volume weighted average price during the period commencing on the trading day immediately following the applicable date
of share combination event and ending on the fifth (5<SUP STYLE="font-size:75%; vertical-align:top">th</SUP>) trading day immediately following such date is less than the exercise price of the Warrants then in effect, then the exercise price of the
Warrants will be reduced to the lowest daily volume weighted average price during such period (subject to a minimum exercise price of the Floor Price), and the number of shares issuable upon exercise will be proportionately adjusted such that the
aggregate exercise price will remain unchanged. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Warrant Stockholder Approval.</I><I></I>&nbsp;Under Nasdaq listing rules, the Warrants may not be
exercised unless and until we obtain the approval of our stockholders (the &#147;Warrant Stockholder Approval&#148;). While we intend to promptly seek stockholder approval, there is no guarantee that the Warrant Stockholder Approval will ever be
obtained. If we are unable to obtain the Warrant Stockholder Approval, the Warrants may not be exercised and will have substantially less value. In addition, we will incur substantial cost, and management will devote substantial time and attention,
in attempting to obtain the Warrant Stockholder Approval. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc930893_8"></A>SELLING STOCKHOLDERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The selling stockholders listed in the table below may from time to time offer and sell up to an aggregate of 1,565,044,860 shares of common stock offered and
issued in the March PIPE Financing pursuant to this prospectus and the applicable prospectus supplements, which consists of: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">up to 3,077,270 shares of common stock; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">up to 19,650,000 shares of common stock issuable upon exercise of
<FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">up to 280,421,380 shares of common stock that could become issuable upon exercise of Series A Common Stock
Warrants; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">up to 1,261,896,210 shares of common stock that could become issuable upon exercise of Series B Common Stock
Warrants. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The number of shares issuable upon the Common Warrants has been calculated assuming the exercise price of the Common Warrants
has been reduced to the Floor Price as discussed under Private Placement above. The selling stockholders have not had any material relationship with us within the past three years, except for the ownership of our equity or debt securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As used in this prospectus, the term &#147;selling stockholders&#148; includes the selling stockholders listed in the table below, together with any
additional selling stockholders listed in a subsequent amendment to this prospectus, and their respective donees, pledgees, assignees, transferees or other
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">successors-in-interest</FONT></FONT> selling shares of common stock or interests in shares of common stock received after the date of this prospectus from a selling stockholder as a
gift, pledge, partnership distribution or other transfer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In accordance with the terms of the Registration Rights Agreement, this prospectus covers the
resale of the maximum number of shares of common stock issuable upon exercise of the Warrants without regard to any limitations on the exercise of such warrants. Under the terms of the <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants and
Common Warrants held by selling stockholders, a selling stockholder may elect to the extent such exercise would cause such selling stockholder, together with its affiliates and attribution parties, to beneficially own a number of shares of common
stock which would exceed 4.99% or 9.99%, as applicable, of our then outstanding shares common stock following such exercise, excluding for purposes of such determination shares of common stock issuable upon exercise of such Warrants that have not
been exercised, to instead receive a <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrant in lieu of shares of common stock. The shares of common stock reported under &#147;Number of Shares Owned&#148; and &#147;Number of Shares Being
Offered&#148; in the table below do not give effect to any such beneficial ownership limitation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The table below lists the selling stockholders and other
information regarding the beneficial ownership of the shares of common stock by each of the selling stockholders as of April&nbsp;2, 2025, assuming the full exercise of the Warrants held by the selling stockholders on that date, without regard to
any limitations on exercises. As of March&nbsp;21, 2025, we had 16,999,626 shares of common stock issued and outstanding. The following table also provides the number of shares of common stock that may be sold by each selling stockholder under this
prospectus and that each selling stockholder will beneficially own assuming all the shares of common stock that may be offered pursuant to this prospectus are sold. Because each selling stockholder may dispose of all, none or some portion of their
shares of common stock, no estimate can be given as to the number of shares of common stock that will be beneficially owned by a selling stockholder upon termination of this offering. For purposes of the table below, however, we have assumed that
after termination of this offering none of the shares of common stock covered by this prospectus will be beneficially owned by the selling stockholders and further assumed that the selling stockholders will not acquire beneficial ownership of any
additional securities during the offering. In addition, the selling stockholders may have sold, transferred or otherwise disposed of, or may sell, transfer or otherwise dispose of, at any time and from time to time, our securities in transactions
exempt from the registration requirements of the Securities Act of 1933, as amended (the &#147;Securities Act&#148;), after the date on which the information in the table is presented. See the section entitled &#147;<I>Plan Of
Distribution</I>.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain selling stockholders currently hold and may acquire shares of common stock in addition to those
registered hereby. In accordance with the rules of the SEC, beneficial ownership includes voting or investment power with respect to securities and includes any shares of common stock issuable pursuant Warrants that are exercisable within 60 days of
March&nbsp;21, 2025, except that the numbers presented in the table below do not give effect to the beneficial ownership limitations discussed above. These shares of common stock are deemed to be outstanding and beneficially owned by the person
holding those Warrants for the purpose of computing the percentage ownership of that person, but they are not treated as outstanding for the purpose of computing the percentage ownership of any other person. The information contained in the
following table is not necessarily indicative of beneficial ownership for any other purpose. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="45%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Beneficial<BR>Ownership<BR>Before this<BR>Offering</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Beneficial Ownership<BR>After this Offering</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>Selling Stockholder</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>Shares<BR>Owned</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>Shares Being<BR>Offered</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of<BR>Shares<BR>Owned</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percentage&nbsp;of<BR>Outstanding<BR>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">AIGH Investment Partners, L.P.<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">91,995,312</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">91,041,775</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">953,537</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5.31</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">WVP Emerging Manager Onshore Fund, LLC &#150; AIGH Series<SUP
STYLE="font-size:75%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">31,692,024</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">31,361,880</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">330,144</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.91</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">AIGH Investment Partners, LLC<SUP STYLE="font-size:75%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,323,940</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,200,300</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">123,640</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8199;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Iroquois Master Fund Ltd.<SUP STYLE="font-size:75%; vertical-align:top">(4)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">32,123,750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">31,708,875</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">414,875</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2.39</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Iroquois Capital Investment Group
LLC<SUP STYLE="font-size:75%; vertical-align:top">(5)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">49,059,762</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">48,442,900</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">616,862</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3.51</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">The Hewlett Fund LP<SUP STYLE="font-size:75%; vertical-align:top">(6)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">47,390,013</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">46,921,270</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">468,743</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2.68</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Aramas Capital Management LLC<SUP STYLE="font-size:75%; vertical-align:top">(7)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,258,241</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,160,130</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">98,111</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8199;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pinz Capital Special Opportunities
Fund&nbsp;lp<SUP STYLE="font-size:75%; vertical-align:top">(8)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,258,241</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,160,130</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">98,111</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8199;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Globis Capital Partners, L.P.<SUP STYLE="font-size:75%; vertical-align:top">(9)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16,320,480</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16,320,480</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Altium Healthcare Long Short Master
Fund&nbsp;LP<SUP STYLE="font-size:75%; vertical-align:top">(10)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">254,545,424</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">254,545,424</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Bigger Capital Fund, LP<SUP STYLE="font-size:75%; vertical-align:top">(11)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">254,545,424</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">254,545,424</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Great Point Capital, LLC<SUP STYLE="font-size:75%; vertical-align:top">(12)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">254,545,424</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">254,545,424</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">L1 Capital Global Opportunities Master
Fund<SUP STYLE="font-size:75%; vertical-align:top">(13)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">254,545,424</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">254,545,424</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">S.H.N Financial Investments Ltd.<SUP STYLE="font-size:75%; vertical-align:top">(14)</SUP></P></TD>

<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">254,545,424</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">254,545,424</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents beneficial ownership of less than one percent (1%) of the outstanding shares of our common stock.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The shares reported under &#147;Beneficial Ownership Before this Offering&#148; consist of the following
securities: (i) 16,553,050 shares of common stock issuable upon the exercise of Series A Common Stock Warrants; (ii)&nbsp;74,488,725 shares of common stock issuable upon the exercise of Series B Common Stock Warrants; and (iii)&nbsp;953,537 shares
of common stock issuable upon the exercise of Series B common stock purchase warrants (&#147;May 2024 Warrants&#148;) issued in a private placement on May&nbsp;9, 2024. The Common Warrants and May 2024 Warrants are subject to a beneficial ownership
limitation of 9.99%, which limitation restricts the selling stockholder from exercising that portion of the Common Warrants and May 2024 Warrants that would result in the selling stockholder and its affiliates owning, after exercise, a number of
shares of common stock in excess of the beneficial ownership limitation. Mr.&nbsp;Orin Hirschman is the managing member of AIGH Capital Management, LLC, a Maryland limited liability company (&#147;AIGH CM&#148;), which is an advisor with respect to
the securities held by AIGH Investment Partners, L.P. (&#147;AIGH LP&#148;). Mr.&nbsp;Hirschman has voting and investment control over the securities indirectly held by AIGH CM, directly held by AIGH LP and directly held by Mr.&nbsp;Hirschman and
his family. The address of Mr.&nbsp;Hirschman and the entities listed is 6006 Berkeley Avenue, Baltimore, Maryland 21209. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The shares reported under &#147;Beneficial Ownership Before this Offering&#148; consist of the following
securities: (i) 5,702,160 shares of common stock issuable upon the exercise of Series A Common Stock Warrants; (ii)&nbsp;25,659,720 shares of common stock issuable upon the exercise of Series B Common Stock Warrants; and (iii) 330,144 shares of
common stock issuable upon the exercise of May 2024 Warrants. The Common Warrants and May 2024 Warrants are subject to a beneficial ownership limitation of 9.99%, which limitation restricts the selling stockholder from exercising that portion of the
Common Warrants and May 2024 Warrants that would result in the selling stockholder and its affiliates owning, after exercise, a number of shares of common stock in excess of the beneficial ownership limitation. Mr.&nbsp;Hirschman is the managing
member of AIGH CM, which is a <FONT STYLE="white-space:nowrap">sub-advisor</FONT> with respect to the securities held by WVP Emerging Manager Onshore Fund, LLC &#150; AIGH Series. Mr.&nbsp;Hirschman has voting and investment control over the
securities indirectly held by AIGH CM and directly held by Mr.&nbsp;Hirschman and his family directly. The address of Mr.&nbsp;Hirschman and the entities listed is 6006 Berkeley Avenue, Baltimore, Maryland 21209. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The shares reported under &#147;Beneficial Ownership Before this Offering&#148; consist of the following
securities: (i) 1,854,600 shares of common stock issuable upon the exercise of Series A Common Stock Warrants; (ii)&nbsp;8,345,700 shares of common stock issuable upon the exercise of Series B Common Stock Warrants; and (iii) 123,640 shares of
common stock issuable upon the exercise of May 2024 Warrants. The Common Warrants and May 2024 Warrants are subject to a beneficial ownership limitation of 9.99%, which limitation restricts the selling stockholder from exercising that portion of the
Common Warrants and May 2024 Warrants that would result in the selling stockholder and its affiliates owning, after exercise, a number of shares of common stock in excess of the beneficial ownership limitation. Mr.&nbsp;Hirschman is the managing
member of AIGH Investment Partners, LLC, a Delaware limited liability company (&#147;AIGH LLC&#148;). Mr.&nbsp;Hirschman has voting and investment control over the securities indirectly held by AIGH LLC and directly held by Mr.&nbsp;Hirschman and
his family directly. The address of Mr.&nbsp;Hirschman and the entities listed is 6006 Berkeley Avenue, Baltimore, Maryland 21209. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The shares reported under &#147;Beneficial Ownership Before this Offering&#148; consist of the following
securities: (i) 30,525 shares of common stock; (ii)&nbsp;5,765,250 shares of common stock issuable upon the exercise of Series A Common Stock Warrants; (iii)&nbsp;25,943,625 shares of common stock issuable upon the exercise of Series B Common Stock
Warrants; and (iv)&nbsp;384,350 shares of common stock issuable upon the exercise of May 2024 Warrants. The Common Warrants and May 2024 Warrants are subject to a beneficial ownership limitation of 4.99%, which limitation restricts the selling
stockholder from exercising that portion of the Common Warrants and May 2024 Warrants that would result in the selling stockholder and its affiliates owning, after exercise, a number of shares of common stock in excess of the beneficial ownership
limitation. Iroquois Capital Management L.L.C. is the investment manager of Iroquois Master Fund, Ltd. Iroquois Capital Management, LLC has voting control and investment discretion over securities held by Iroquois Master Fund. As Managing Members of
Iroquois Capital Management, LLC. Richard Abbe and Kimberly Page make voting and investment decisions on behalf of Iroquois Capital Management, LLC in its capacity as investment manager to Iroquois Master Fund Ltd. As a result of the foregoing,
Mr.&nbsp;Abbe and Mrs.&nbsp;Page may be deemed to have beneficial ownership (as determined under Section&nbsp;13(d) of the Securities Exchange Act) of the securities held by Iroquois Capital Management and Iroquois Master Fund. The address for
Iroquois Master Fund Ltd., Mr.&nbsp;Abbe and Mrs.&nbsp;Page is c/o Iroquois Capital Management, LLC, 2 Overhill Road, Suite 400, Scarsdale, New York 10583. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The shares reported under &#147;Beneficial Ownership Before this Offering&#148; consist of the following
securities: (i) 29,875 shares of common stock; (ii)&nbsp;8,807,800 shares of common stock issuable upon the exercise of Series A Common Stock Warrants; (iii)&nbsp;39,635,100 shares of common stock issuable upon the exercise of Series B Common Stock
Warrants; and (iv)&nbsp;586,987 shares of common stock issuable upon the exercise of May 2024 Warrants. The Common Warrants and May 2024 Warrants are subject to a beneficial ownership limitation of 4.99%, which limitation restricts the selling
stockholder from exercising that portion of the Common Warrants and May 2024 Warrants that would result in the selling stockholder and its affiliates owning, after exercise, a number of shares of common stock in excess of the beneficial ownership
limitation. Mr.&nbsp;Richard Abbe is the managing member of Iroquois Capital Investment Group LLC. Mr.&nbsp;Abbe has voting control and investment discretion over securities held by Iroquois Capital Investment
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
Group LLC. The address for Iroquois Capital Investment Group LLC and Mr.&nbsp;Abbe is 2 Over Hill Rd., Suite 500, Scarsdale, New York 10583. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The shares reported under &#147;Beneficial Ownership Before this Offering&#148; consist of the following
securities: (i) 8,531,140 shares of common stock issuable upon the exercise of Series A Common Stock Warrants; (ii)&nbsp;38,390,130 shares of common stock issuable upon the exercise of Series B Common Stock Warrants; and (v) 468,743 shares of common
stock issuable upon the exercise of May 2024 Warrants. The Common Warrants, and May 2024 Warrants are subject to a beneficial ownership limitation of 4.99%, which limitation restricts the selling stockholder from exercising that portion of the
Common Warrants and May 2024 Warrants that would result in the selling stockholder and its affiliates owning, after exercise, a number of shares of common stock in excess of the beneficial ownership limitation. Mr.&nbsp;Martin Chopp, the general
partner of the The Hewlett Fund LP (&#147;Hewlett&#148;), has voting and investment control over the securities held by Hewlett. The address for Hewlett and Mr.&nbsp;Chopp is 100 Merrick Road, Suite 400W, Rockville Centre, New York 11570.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(7)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The shares reported under &#147;Beneficial Ownership Before this Offering&#148; consist of the following
securities: (i) 1,483,660 shares of common stock issuable upon the exercise of Series A Common Stock Warrants; (ii)&nbsp;6,676,470 shares of common stock issuable upon the exercise of Series B Common Stock Warrants; and (iii) 98,111 shares of common
stock issuable upon the exercise of May 2024 Warrants. The Common Warrants and May 2024 Warrants are subject to a beneficial ownership limitation of 4.99%, which limitation restricts the selling stockholder from exercising that portion of the Common
Warrants and May 2024 Warrants that would result in the selling stockholder and its affiliates owning, after exercise, a number of shares of common stock in excess of the beneficial ownership limitation. Mr.&nbsp;Sam Ginzburg has sole voting and
dispositive power over the shares held by Aramas Capital Management LLC. The address for Aramas Capital Management LLC and Mr.&nbsp;Ginzburg is c/o Aramas Capital Holdings LLC, 19 Orchard Street, Manhasset, New York 11030. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(8)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The shares reported under &#147;Beneficial Ownership Before this Offering&#148; consist of the following
securities: (i) 1,483,660 shares of common stock issuable upon the exercise of Series A Common Stock Warrants; (ii)&nbsp;6,676,470 shares of common stock issuable upon the exercise of Series B Common Stock Warrants; and (iii) 98,111 shares of common
stock issuable upon the exercise of May 2024 Warrants. The Common Warrants and May 2024 Warrants are subject to a beneficial ownership limitation of 4.99%, which limitation restricts the selling stockholder from exercising that portion of the Common
Warrants and May 2024 Warrants that would result in the selling stockholder and its affiliates owning, after exercise, a number of shares of common stock in excess of the beneficial ownership limitation. Mr.&nbsp;Matthew&nbsp;L. Pinz has sole voting
and dispositive power over the shares held by Pinz Capital Special Opportunities Fund. The address for Pinz Capital Special Opportunities Fund and Mr.&nbsp;Pinz is 80 Dogwood Avenue, Roslyn Harbor, New&nbsp;York 11576. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(9)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The shares reported under &#147;Beneficial Ownership Before this Offering&#148; consist of the following
securities: (i)&nbsp;2,967,360 shares of common stock issuable upon the exercise of Series A Common Stock Warrants; and (ii)&nbsp;13,353,120 shares of common stock issuable upon the exercise of Series B Common Stock Warrants. The Common Warrants are
subject to a beneficial ownership limitation of 4.99%, which limitation restricts the selling stockholder from exercising that portion of the Common Warrants that would result in the selling stockholder and its affiliates owning, after exercise, a
number of shares of common stock in excess of the beneficial ownership limitation. Mr.&nbsp;Paul Packer is the managing member of Globis Capital Partners, L.P. and has voting and investment control over the securities held by Globis Capital
Partners, L.P. The address for Globis Capital Partners, L.P. and Mr.&nbsp;Packer is 7100 W. Camino Real, Suite <FONT STYLE="white-space:nowrap">302-48,</FONT> Boca Raton, FL&nbsp;33433. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(10)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The shares reported under &#147;Beneficial Ownership Before this Offering&#148; consist of the following
securities purchased by Altium Healthcare Long Short Master Fund LP in the March PIPE Financing: (i) 435,454 shares of common stock; (ii) 4,110,000 shares of common stock issuable upon the exercise of
<FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants; (iii) 45,454,540 shares of common stock issuable upon the exercise of Series A Common Stock Warrants; and (iv) 204,545,430 shares of common stock issuable upon the exercise of Series B
Common Stock Warrants. The <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants and Common Warrants are subject to a beneficial ownership limitation of 4.99%, which limitation restricts the selling stockholder from exercising that portion of
the <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants and Common Warrants that would result in the selling stockholder owning, after </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
exercise, a number of shares of common stock in excess of the beneficial ownership limitation. The address for Altium Healthcare Long Short Master Fund LP is Altium Capital Management LLC, 152
West 57th&nbsp;Street, 20th Floor, New York, New York 10019. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(11)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The shares reported under &#147;Beneficial Ownership Before this Offering&#148; consist of the following
securities purchased by Bigger Capital Fund, LP in the March PIPE Financing: (i) 435,454 shares of common stock; (ii) 4,110,000 shares of common stock issuable upon the exercise of <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants; (iii)
45,454,540 shares of common stock issuable upon the exercise of Series A Common Stock Warrants; and (iv) 204,545,430 shares of common stock issuable upon the exercise of Series B Common Stock Warrants. The
<FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants and Common Warrants are subject to a beneficial ownership limitation of 4.99%, which limitation restricts the selling stockholder from exercising that portion of the <FONT
STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants and Common Warrants that would result in the selling stockholder owning, after exercise, a number of shares of common stock in excess of the beneficial ownership limitation. The address for
Bigger Capital Fund, LP is 11700 W Charleston Blvd. <FONT STYLE="white-space:nowrap">170-659,</FONT> Las Vegas, Nevada 89135. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(12)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The shares reported under &#147;Beneficial Ownership Before this Offering&#148; consist of the following
securities purchased by Great Point Capital, LLC in the March PIPE Financing: (i) 885,454 shares of common stock; (ii) 3,660,000 shares of common stock issuable upon the exercise of <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants; (iii)
45,454,540 shares of common stock issuable upon the exercise of Series A Common Stock Warrants; and (iv)&nbsp;204,545,430 shares of common stock issuable upon the exercise of Series B Common Stock Warrants. The
<FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants and Common Warrants are subject to a beneficial ownership limitation of 9.99%, which limitation restricts the selling stockholder from exercising that portion of the <FONT
STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants and Common Warrants that would result in the selling stockholder owning, after exercise, a number of shares of common stock in excess of the beneficial ownership limitation. The address for Great
Point Capital, LLC is 12301 Research Blvd, Bldg <FONT STYLE="white-space:nowrap">4-270,</FONT> Austin, Texas 78759. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(13)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The shares reported under &#147;Beneficial Ownership Before this Offering&#148; consist of the following
securities purchased by L1 Capital Global Opportunities Master Fund in the March PIPE Financing: (i) 435,454 shares of common stock; (ii) 4,110,000 shares of common stock issuable upon the exercise of
<FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants; (iii) 45,454,540 shares of common stock issuable upon the exercise of Series A Common Stock Warrants; and (iv) 204,545,430 shares of common stock issuable upon the exercise of Series B
Common Stock Warrants. The <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants and Common Warrants are subject to a beneficial ownership limitation of 4.99%, which limitation restricts the selling stockholder from exercising that portion of
the <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants and Common Warrants that would result in the selling stockholder owning, after exercise, a number of shares of common stock in excess of the beneficial ownership limitation. The address
for L1 Capital Global Opportunities Master Fund is 161A Shedden Road, 1 Artillery Court, PO Box 10085, Grand Cayman <FONT STYLE="white-space:nowrap">KY1-1001,</FONT> Cayman Islands. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(14)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The shares reported under &#147;Beneficial Ownership Before this Offering&#148; consist of the following
securities purchased by S.H.N Financial Investments Ltd. in the March PIPE Financing: (i) 885,454 shares of common stock; (ii) 3,660,000 shares of common stock issuable upon the exercise of <FONT STYLE="white-space:nowrap">Pre-Funded</FONT>
Warrants; (iii)&nbsp;45,454,540 shares of common stock issuable upon the exercise of Series A Common Stock Warrants; and (iv) 204,545,430 shares of common stock issuable upon the exercise of Series B Common Stock Warrants. The <FONT
STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants and Common Warrants are subject to a beneficial ownership limitation of 9.99%, which limitation restricts the selling stockholder from exercising that portion of the <FONT
STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants and Common Warrants that would result in the selling stockholder owning, after exercise, a number of shares of common stock in excess of the beneficial ownership limitation. The address for S.H.N
Financial Investments Ltd. is Arik Einstein 3, Herzliya, Israel. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc930893_9"></A>PLAN OF DISTRIBUTION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The selling stockholders, which as used in this prospectus includes the selling stockholders listed in the section of this prospectus entitled
&#147;<I>Selling Stockholders</I>,&#148; together with any additional selling stockholders listed in a subsequent amendment to this prospectus, and their respective donees, pledgees, assignees, transferees or other <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">successors-in-interest</FONT></FONT> selling shares of common stock or interests in shares of common stock received after the date of this prospectus from a selling stockholder as a gift, pledge, partnership distribution
or other transfer, may, from time to time, sell, transfer or otherwise dispose of any or all of their shares of common stock or interests in shares of common stock on any stock exchange, market or trading facility on which the shares are traded or
in private transactions. These dispositions may be at fixed prices, at prevailing market prices at the time of sale, at prices related to the prevailing market price, at varying prices determined at the time of sale, or at negotiated prices. The
selling stockholders may use any one or more of the following methods when disposing of their shares of common stock or interests therein: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">on any national securities exchange or quotation service on which the shares of common stock may be listed or
quoted at the time of sale; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT> market;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">ordinary brokerage transactions and transactions in which the broker-dealer solicits purchasers;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">block trades in which the broker-dealer will attempt to sell the shares of common stock as agent but may position
and resell a portion of the block as principal to facilitate the transaction; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">through brokers, dealers or underwriters that may act solely as agents; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">purchases by a broker-dealer as principal and resale by the broker-dealer for its account; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an exchange distribution in accordance with the rules of the applicable exchange; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">privately negotiated transactions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delivery of shares in settlement of short sales; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in transactions through broker-dealers that agree with the selling stockholders to sell a specified number of
such shares of common stock at a stipulated price per security; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">through the writing or settlement of options or other hedging transactions, whether through an options exchange
or otherwise; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a combination of any such methods of disposition; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any other method permitted pursuant to applicable law. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The selling stockholders may also sell the shares of common stock under Rule 144 or any other exemption from registration under the Securities Act, if
available, rather than under this prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Broker-dealers engaged by the selling stockholders may arrange for other brokers-dealers to participate in
sales. Broker-dealers, underwriters and other agents may receive commissions or discounts from the selling stockholders (or, if any broker-dealer acts as agent for the purchaser of shares of common stock, from the purchaser) in amounts to be
negotiated, but, except as set forth in a supplement to this prospectus, in the case of an agency transaction not in excess of a customary brokerage commission in compliance with Financial Industry Regulatory Authority (&#147;FINRA&#148;) Rule 2121,
and in the case of a principal transaction a markup or markdown in compliance with FINRA Rule 2121. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The selling stockholders may from time to time pledge
or grant a security interest in some or all of the shares of common stock owned by them and the pledgee or other secured party, transferee or other successor in interest may sell shares of common stock from time to time under this prospectus, or
under a supplement or amendment </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
to this prospectus under Rule 424(b)(3) under, or other applicable provision of, the Securities Act amending the list of selling stockholders to include the pledgee, secured party, transferee or
other <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">successors-in-interest</FONT></FONT> as selling stockholders under this prospectus. The selling stockholders also may transfer the shares of common stock in other circumstances
in which case the donees, pledgees, assignees, transferees or other <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">successors-in-interest</FONT></FONT> may be the selling beneficial owners for purposes of this prospectus and may
sell such shares of common stock from time to time under this prospectus after an amendment or supplement has been filed under Rule 424(b)(3) under, or another applicable provision of, the Securities Act, amending, if necessary, the list of selling
stockholders to include the donees, pledgees, assignees, transferees or other <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">successors-in-interest</FONT></FONT> as selling stockholders under this prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon being notified in writing by the selling stockholder that any material arrangement has been entered into with a broker-dealer for the sale of shares of
common stock through a block trade, special offering, exchange distribution or secondary distribution or a purchase by a broker or dealer, a supplement to this prospectus, if required, pursuant to Rule 424(b) under the Securities Act will be filed,
disclosing (i)&nbsp;the name of each such selling stockholder and of the participating broker-dealer(s), (ii) the number of shares of common stock involved, (iii)&nbsp;the price at which such shares of common stock were sold, (iv)&nbsp;the
commissions paid or discounts or concessions allowed to such broker-dealer(s), where applicable, (v)&nbsp;that such broker-dealer(s) did not conduct any investigation to verify the information set out or incorporated by reference in this prospectus,
if applicable, and (vi)&nbsp;other facts material to the transaction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The selling stockholders also may transfer the shares of common stock in other
circumstances, in which case the donees, pledgees, assignees, transferees or other <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">successors-in-interest</FONT></FONT> will be the selling beneficial owners for purposes of this
prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the sale of the shares of common stock or interests therein, the selling stockholders may enter into hedging transactions
after the effective date of the registration statement of which this prospectus is a part with broker-dealers or other financial institutions, which may in turn engage in short sales of the shares of common stock in the course of hedging the
positions they assume. The selling stockholders may also sell the shares of common stock short after the effective date of the registration statement of which this prospectus forms a part and deliver these shares of common stock to close out their
short positions, or loan or pledge the shares of common stock to broker-dealers that in turn may sell these shares of common stock. The selling stockholders may also enter into option or other transactions after the effective date of the
registration statement of which this prospectus forms a part with broker-dealers or other financial institutions or create one or more derivative securities that require the delivery to such broker-dealer or other financial institution of shares of
common stock offered by this prospectus, which securities such broker-dealer or other financial institution may resell pursuant to this prospectus (as supplemented or amended to reflect such transaction), including in the short sale transactions.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The selling stockholders and any broker-dealers or agents that are involved in selling the shares of common stock may be deemed to be
&#147;underwriters&#148; within the meaning of the Securities Act in connection with such sales. In such event, any commissions received by such broker-dealers or agents and any profit on the resale of the shares of common stock purchased by them
may be deemed to be underwriting commissions or discounts under the Securities Act. Each selling stockholder has informed the Company that it does not have any written or oral agreement or understanding, directly or indirectly, with any person to
distribute the shares of common stock. Any compensation paid to underwriters, broker-dealers or agents in connection with the offering of the shares of common stock, and any discounts, concessions or commissions allowed by underwriters to
participating dealers will be provided in the applicable prospectus supplement and shall comply with the rules and requirements of FINRA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company is
required to pay certain fees and expenses incurred by the Company incident to the registration of the shares of common stock. The Company has agreed to indemnify the selling stockholders against certain losses, claims, damages and liabilities to
which they may become subject, including liabilities under the Securities Act. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We agreed to keep this prospectus effective until the earlier of (i)&nbsp;the date that such shares of
common stock become eligible for resale without volume or <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">manner-of-sale</FONT></FONT> restrictions and without current public information pursuant to Rule 144 and certain other
conditions have been satisfied, or (ii)&nbsp;all of the shares of common stock have been sold pursuant to this prospectus or Rule 144 under the Securities Act or any other rule of similar effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There can be no assurance that any selling stockholder will sell any or all of the shares of common stock registered pursuant to the registration statement of
which this prospectus forms a part. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under applicable rules and regulations under the Exchange Act, any person engaged in the distribution of the resale
securities may not simultaneously engage in market-making activities with respect to the common stock for the applicable restricted period, as defined in Regulation M, prior to the commencement of the distribution. In addition, the selling
stockholders will be subject to applicable provisions of the Exchange Act and the rules and regulations thereunder, including Regulation M, which may limit the timing of purchases and sales of the common stock by the selling stockholders or any
other person. Regulation M may also restrict the ability of any person engaged in the distribution of the shares of common stock to engage in market-making activities with respect to the shares of common stock. All of the foregoing may affect the
marketability of the shares of common stock and the ability of any person or entity to engage in market-making activities with respect to the shares of common stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc930893_10"></A>LEGAL MATTERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Hogan Lovells US LLP, Houston, Texas, will pass upon the validity of the shares of our common stock offered by this prospectus. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc930893_11"></A>EXPERTS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
consolidated financial statements of Plus Therapeutics, Inc. as of December&nbsp;31, 2024 and 2023 and for the years then ended incorporated by reference in this prospectus and in the Registration Statement have been so incorporated in reliance on
the report of BDO USA, P.C., an independent registered public accounting firm, given on the authority of said firm as experts in auditing and accounting. The report on the consolidated financial statements contains an explanatory paragraph regarding
the Company&#146;s ability to continue as a going concern. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc930893_12"></A>WHERE YOU CAN FIND ADDITIONAL INFORMATION
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus is part of the registration statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT> that we filed with the SEC under the
Securities Act and does not contain all the information set forth or incorporated by reference in the registration statement. Whenever a reference is made in this prospectus to any of our contracts, agreements or other documents, the reference may
not be complete and you should refer to the exhibits that are a part of the registration statement or the exhibits to the reports or other documents incorporated by reference into this prospectus for a copy of such contract, agreement or other
document. You may obtain copies of the registration statement and its exhibits via the SEC&#146;s EDGAR database. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We file annual, quarterly and current
reports, proxy statements and other information with the SEC under the Exchange Act. The SEC maintains a website that contains reports, proxy and information statements and other information regarding issuers, including us, that file electronically
with the SEC. You may obtain documents that we file with the SEC at www.sec.gov. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our website address is www.plustherapeutics.com. We do not incorporate
the information on or accessible through our website into this prospectus or any prospectus supplement, and you should not consider any information on, or that can be accessed through, our website as part of this prospectus or any prospectus
supplement. Our website address is included in this prospectus as an inactive textual reference only. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc930893_13"></A>INFORMATION INCORPORATED BY REFERENCE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The registration statement of which prospectus is a part incorporates by reference important business and financial information about our company that is not
included in or delivered with this document. The information incorporated by reference is considered to be part of this prospectus, and the SEC allows us to &#147;incorporate by reference&#148; the information we file with it, which means that we
can disclose important information to you by referring you to those documents instead of having to repeat the information in this prospectus. Any statement contained in any document incorporated or deemed to be incorporated by reference herein shall
be deemed to be modified or superseded for purposes of this prospectus to the extent that a statement contained in or omitted from this prospectus or any accompanying prospectus supplement, or in any other subsequently filed document which also is
or is deemed to be incorporated by reference herein, modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this prospectus. We
incorporate by reference: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the fiscal year ended
December&nbsp;31, 2024, filed with the SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001095981/000095017025047698/pstv-20241231.htm">March<U></U>&nbsp;31, 2025</A>; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our Current Reports on <FONT STYLE="white-space:nowrap">Form&nbsp;8-K&nbsp;filed</FONT> with the SEC on&nbsp;
<A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001095981/000119312525028151/d916701d8k.htm">February<U></U>&nbsp;
18, 2025</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001095981/000119312525045305/d875007d8k.htm">March<U></U>&nbsp;
4, 2025</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001095981/000119312525050390/d938890d8k.htm">March<U></U>&nbsp;
10, 2025</A>, and <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001095981/000095017025055883/pstv-20250417.htm">April&nbsp;18, 2025</A>; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The description of our shares of common stock contained in the registration statement on 10/A, filed with the SEC
on July&nbsp;16, 2001 (File <FONT STYLE="white-space:nowrap">No.&nbsp;000-32501),</FONT> as updated by <A HREF="http://www.sec.gov/Archives/edgar/data/1095981/000156459020014165/pstv-ex41_202.htm">Exhibit 4.1</A> to our Annual Report on Form <FONT
STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2020, filed with the SEC on March&nbsp;30, 2021, as well as any additional amendments or reports filed for the purpose of updating such description. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We also incorporate by reference into this prospectus any further filings we make with the SEC under Sections&nbsp;13(a), 13(c), 14 or 15(d) of the Exchange
Act (other than portions of those made pursuant to Item 2.02 or Item 7.01 of a Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> or other information &#147;furnished&#148; and not filed with the SEC), including all filings filed
after the date hereof and prior to the completion of an offering of securities under this prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have filed with the SEC this registration
statement under the Securities Act, covering the shares of common stock to be offered and sold pursuant to this prospectus and any applicable prospectus supplement. This prospectus does not contain all of the information included in the registration
statement, some of which is contained in exhibits to the registration statement. The registration statement, including the exhibits, can be read at the SEC website referred to above under &#147;Where You Can Find More Information.&#148; Any
statement made in this prospectus or any prospectus supplement concerning the contents of any contract, agreement or other document is only a summary of the actual contract, agreement or other document. If we have filed any contract, document,
agreement or other document as an exhibit to the registration statement or any other document incorporated herein by reference, you should read the exhibit for a more complete understanding of the document or matter involved. Each statement
regarding a contract, agreement or other document is qualified in its entirety by reference to the actual document. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You may request a free copy of any of
the documents incorporated by reference in this prospectus by writing to us at Plus Therapeutics, Inc., 2710 Reed Road, Suite 160, Houston, Texas 77051. Exhibits to the filings will not be sent, however, unless they have specifically been
incorporated by reference in this prospectus or any accompanying prospectus supplement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PART II </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INFORMATION NOT REQUIRED IN PROSPECTUS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&#8201;14. Other Expenses of Issuance and Distribution. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table sets forth an estimate of the fees and expenses payable by us in connection with the issuance and distribution of the shares of common
stock hereby. All the amounts shown are estimates, except for the SEC registration fee. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="83%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SEC registration fee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">194,083</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accountants&#146; fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Legal fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">50,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Miscellaneous fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,917</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">280,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Discounts, concessions, commissions and similar selling expenses attributable to the sale of shares of common stock covered by
this prospectus will be borne by the selling stockholders. We will pay all expenses (other than discounts, concessions, commissions and similar selling expenses) relating to the registration of the resale of the shares of common stock with the SEC,
as estimated in the table above. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&#8201;15. Indemnification of Directors and Officers. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company is a Delaware corporation. Section&nbsp;145(a) of the General Corporation Law of the State of Delaware (&#147;DGCL&#148;) provides that a Delaware
corporation may indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative, other than an action by or
in the right of the corporation, by reason of the fact that such person is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of another
corporation, partnership, joint venture, trust or other enterprise, against expenses (including attorneys&#146; fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by the person in connection with such action,
suit or proceeding if the person acted in good faith and in a manner the person reasonably believed to be in or not opposed to the best interests of the corporation, and, with respect to any criminal action or proceeding, had no reasonable cause to
believe his or her conduct was unlawful. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Section&nbsp;145(b) of the DGCL provides that a Delaware corporation may indemnify any person who was or is a
party or is threatened to be made a party to any threatened, pending or completed action or suit by or in the right of the corporation to procure a judgment in its favor by reason of the fact that such person acted in any of the capacities set forth
above, against expenses (including attorneys&#146; fees) actually and reasonably incurred by such person in connection with the defense or settlement of such action or suit if the person acted in good faith and in a manner the person reasonably
believed to be in, or not opposed to, the best interests of the corporation, except that no indemnification shall be made in respect of any claim, issue or matter as to which such person shall have been adjudged to be liable to the corporation,
unless and only to the extent that the Court of Chancery or the court in which such action or suit was brought shall determine, upon application, that, despite the adjudication of liability but in view of all the circumstances of the case, such
person is fairly and reasonably entitled to indemnity for such expenses which the court shall deem proper. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Further subsections of DGCL Section&nbsp;145
provide that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to the extent a present or former director or officer of a corporation has been successful on the merits or
otherwise in the defense of any action, suit or proceeding referred to in subsections (i)&nbsp;and (ii) of </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
Section&nbsp;145 or in the defense of any claim, issue or matter therein, such person shall be indemnified against expenses, including attorneys&#146; fees, actually and reasonably incurred by
such person in connection therewith; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the indemnification and advancement of expenses provided for pursuant to Section&nbsp;145 shall not be deemed
exclusive of any other rights to which those seeking indemnification or advancement of expenses may be entitled under any bylaw, agreement, vote of shareholders or disinterested directors or otherwise; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the corporation shall have the power to purchase and maintain insurance of behalf of any person who is or was a
director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, against any
liability asserted against such person and incurred by such person in any such capacity, or arising out of such person&#146;s status as such, whether or not the corporation would have the power to indemnify such person against such liability under
Section&nbsp;145. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As used in this Item 15, the term &#147;proceeding&#148; means any threatened, pending or completed action, suit or
proceeding, whether or not by or in the right of the Company, and whether civil, criminal, administrative, investigative or otherwise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Section&nbsp;145
of the DGCL makes provision for the indemnification of officers and directors in terms sufficiently broad to indemnify officers and directors of the Company under certain circumstances from liabilities (including reimbursement for expenses incurred)
arising under the Securities Act. The Company&#146;s organizational documents provide, in effect, that, to the fullest extent and under the circumstances permitted by Section&nbsp;145 of the DGCL, the Company will indemnify any and all of its
officers and directors. The Company has entered into indemnification agreements with its officers and directors. The Company may, in its discretion, similarly indemnify its employees and agents. The Company&#146;s certificate of incorporation, as
amended, also relieves its directors from monetary damages to the Company or its stockholders for breach of such director&#146;s fiduciary duty as a director to the fullest extent permitted by the DGCL. Under Section&nbsp;102(b)(7) of the DGCL, a
corporation may relieve its directors from personal liability to such corporation or its stockholders for monetary damages for any breach of their fiduciary duty as directors except (i)&nbsp;for a breach of the duty of loyalty, (ii)&nbsp;for failure
to act in good faith, (iii)&nbsp;for intentional misconduct or knowing violation of law, (iv)&nbsp;for willful or negligent violations of certain provisions in the DGCL imposing certain requirements with respect to stock repurchases, redemptions and
dividends or (v)&nbsp;for any transactions from which the director derived an improper personal benefit. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has purchased insurance policies
that, within the limits and subject to the terms and conditions thereof, cover certain expenses and liabilities that may be incurred by directors and officers in connection with proceedings that may be brought against them as a result of an act or
omission committed or suffered while acting as a director or officer of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have entered into the Registration Rights Agreement with the
selling stockholders of the shares of common stock registered hereby which obligates the parties to indemnify, under certain circumstances, the other party, its officers, directors, and controlling persons within the meaning of the Securities Act
against certain liabilities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&#8201;16. Exhibits. </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="52%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center"><B>Incorporated by Reference</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" ALIGN="center"><B>Exhibit<BR>Number</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>Description</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Form</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>File Number</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Exhibit</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Filing Date</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&#8199;&#8199;3.1</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/0001095981/000114036116057505/ex3_1.htm">Composite Certificate of Incorporation. </A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">10-K</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">001-34375</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">03/11/2016</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&#8199;&#8199;3.2</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/0001095981/000109598116000063/ex3_1.htm">Certificate of Amendment to Amended and Restated Certificate. </A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">8-K</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">001-34375</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">05/10/2016</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&#8199;&#8199;3.3</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/0001095981/000156459018014245/cytx-ex31_6.htm">Certificate of Amendment to Amended and Restated Certificate. </A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">8-K</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">001-34375</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">05/23/2018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&#8199;&#8199;3.4</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1095981/000156459019026454/cytx-ex31_6.htm">Certificate of Amendment to Amended and Restated Certificate. </A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">8-K</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">001-34375</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">07/29/2019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&#8199;&#8199;3.5</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/0001095981/000156459019028996/pstv-ex31_18.htm">Certificate of Amendment to Amended and Restated Certificate. </A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">8-K</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">001-34375</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">08/06/2019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&#8199;&#8199;3.6</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/0001095981/000119312523127227/d475493dex31.htm">Certificate of Amendment to Amended and Restated Certificate. </A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">8-K</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">001-34375</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">04/28/2023</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&#8199;&#8199;3.7</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/0001095981/000119312521277718/d164672dex31.htm">Amended and Restated Bylaws of Plus Therapeutics, Inc. </A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">8-K</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">001-34375</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">09/21/2021</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&#8199;&#8199;3.8</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1095981/000156459017024297/cytx-ex31_6.htm">Certificate of Designation of Preferences, Rights and Limitations of Series B Convertible Preferred Stock. </A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">8-K</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">001-34375</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11/28/2017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&#8199;&#8199;3.9</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1095981/000156459018017443/cytx-ex31_7.htm">Certificate of Designation of Preferences, Rights and Limitations of Series C Convertible Preferred Stock. </A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">8-K</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">001-34375</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">07/25/2018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&#8199;&#8199;4.1</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1095981/000156459018005136/cytx-ex433_277.htm">Form of Common Stock Certificate. </A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">10-K</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">001-34375</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">03/09/2018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&#8199;&#8199;4.2</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1095981/000119312525045305/d875007dex41.htm">Form of <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrant. </A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">8-K</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">011-34375</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">03/04/2025</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&#8199;&#8199;4.3</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1095981/000119312525045305/d875007dex42.htm">Form of Series A Warrant. </A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">8-K</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">011-34375</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">03/04/2025</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&#8199;&#8199;4.4</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1095981/000119312525045305/d875007dex43.htm">Form of Series B Warrant. </A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">8-K</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">011-34375</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">03/04/2025</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&#8199;&#8199;5.1**</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Opinion of Hogan Lovells US LLP.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&#8199;23.1*</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="d930893dex231.htm">Consent of Independent Registered Public Accounting Firm. </A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&#8199;23.2**</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Consent of Hogan Lovells US LLP (included in Exhibit 5.1 hereto).</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&#8199;24.1</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1095981/000119312525073481/d930893dex241.htm">Power of Attorney. </A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">S-3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">333-286393</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24.1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">04/04/2025</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&#8199;24.2*</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="d930893dex242.htm">Power of Attorney. </A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>107.1</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1095981/000119312525073481/d930893dexfilingfees.htm">Filing Fee Table. </A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">S-3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">333-286393</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">107.1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">04/04/2025</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Filed herewith. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">**</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To be filed by amendment. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&#8201;17. Undertakings </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(a) The undersigned
registrant hereby undertakes: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(1) To file, during any period in which offers or sales are being made, a post-effective amendment to this
registration statement: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to include any prospectus required by Section&nbsp;10(a)(3) of the Securities Act; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to reflect in the prospectus any facts or events arising after the effective date of the registration statement
(or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in
volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus
filed with the SEC pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than 20% change in the maximum aggregate offering price set forth in the &#147;Calculation of Filing Fee Table&#148; in the effective
registration statement; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to include any material information with respect to the plan of distribution not previously disclosed in the
registration statement or any material change to such information in the registration statement; </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>provided, however</I>, that
Paragraphs (a)(1)(i), (a)(1)(ii), and (a)(1)(iii) of this section do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the SEC by the registrant
pursuant to Section&nbsp;13 or Section&nbsp;15(d) of the Exchange Act that are incorporated by reference in the registration statement, or is contained in a form of prospectus filed pursuant to Rule 424(b) that is part of the registration statement.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(2) That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be
a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(3) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the
termination of the offering; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(4) That, for the purpose of determining liability under the Securities Act to any purchaser: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Each prospectus filed by the registrant pursuant to Rule 424(b)(3) shall be deemed to be part of the
registration statement as of the date the filed prospectus was deemed part of and included in the registration statement; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Each prospectus required to be filed pursuant to Rule 424(b)(2), (b)(5), or (b)(7) as part of a registration
statement in reliance on Rule 430B relating to an offering made pursuant to Rule&nbsp;415(a)(1)(i), (vii), or (x)&nbsp;for the purpose of providing the information required by Section&nbsp;10(a) of the Securities Act shall be deemed to be part of
and included in the registration statement as of the earlier of the date such form of prospectus is first used after effectiveness or the date of the first contract of sale of securities in the offering described in the prospectus. As provided in
Rule 430B, for liability purposes of the issuer and any person that is at that date an underwriter, such date shall be deemed to be a new effective date of the registration statement relating to the securities in the registration statement to which
that prospectus relates, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. Provided, however, that no statement made in a registration statement or prospectus that is part of the
registration statement or made in a document incorporated or deemed incorporated by reference into the registration statement or prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale prior to
such effective date, supersede or modify any statement that was made in the registration statement or prospectus that was part of the registration statement or made in any such document immediately prior to such effective date.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(5) That, for the purpose of determining liability of the registrant under the Securities Act to any purchaser in the
initial distribution of the securities: The undersigned registrant undertakes that in a primary offering of securities of the undersigned registrant pursuant to this registration statement, regardless of the underwriting method used to sell the
securities to the purchaser, if the securities are offered or sold to such purchaser by means of any of the following communications, the undersigned registrant will be a seller to the purchaser and will be considered to offer or sell such
securities to such purchaser: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Any preliminary prospectus or prospectus of the undersigned registrant relating to the offering required to be
filed pursuant to Rule 424; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Any free writing prospectus relating to the offering prepared by or on behalf of the undersigned registrant or
used or referred to by the undersigned registrant; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The portion of any other free writing prospectus relating to the offering containing material information about
the undersigned registrant or its securities provided by or on behalf of the undersigned registrant; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iv)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Any other communication that is an offer in the offering made by the undersigned registrant to the purchaser.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(b) that, for purposes of determining any liability under the Securities Act, each filing of the registrant&#146;s annual report
pursuant to Section&nbsp;13(a) or Section&nbsp;15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan&#146;s annual report pursuant to Section&nbsp;15(d) of the Exchange Act) that is incorporated by reference in
the registration statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(c) Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the
registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the SEC such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the
event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or
proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a
court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Act, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements
for filing on Form <FONT STYLE="white-space:nowrap">S-3</FONT> and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Houston, State of Texas, on April&nbsp;23, 2025.
</P>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>PLUS THERAPEUTICS, INC.</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">By:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/S/ Marc H. Hedrick</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Marc H. Hedrick, M.D.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>President and Chief Executive Officer</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the&nbsp;Securities Act, this registration statement has been signed by the following persons
in the capacities held and on the dates indicated. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="39%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="44%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="13%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Signature</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Title</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Date</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">/S/ Marc H. Hedrick</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>M<SMALL>ARC</SMALL> H. H<SMALL>EDRICK</SMALL>, M.D.</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">President, Chief Executive Officer and Director<BR><I>(Principal Executive Officer)</I></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="right">April&nbsp;23, 2025</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">/S/ Andrew Sims</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>A<SMALL>NDREW</SMALL> S<SMALL>IMS</SMALL></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">Chief Financial Officer<BR><I>(Principal Financial and Accounting Officer)</I></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="right">April&nbsp;23, 2025</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">*</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>R<SMALL>ICHARD</SMALL> J. H<SMALL>AWKINS</SMALL></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">Chair of the Board of Directors</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="right">April&nbsp;23, 2025</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">*</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>H<SMALL>OWARD</SMALL> C<SMALL>LOWES</SMALL></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="right">April&nbsp;23, 2025</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">*</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>K<SMALL>YLE</SMALL> G<SMALL>USE</SMALL></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">April&nbsp;23,&nbsp;2025</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">*</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>A<SMALL>N</SMALL> V<SMALL>AN</SMALL> E<SMALL>S</SMALL>-J<SMALL>OHANSSON</SMALL>, M.D.</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="right">April&nbsp;23, 2025</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">*</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>R<SMALL>OBERT</SMALL> L<SMALL>ENK</SMALL>, PH.D</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="right">April&nbsp;23, 2025</TD></TR>
</TABLE>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="11%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="88%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">*BY:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/S/ Marc H. Hedrick</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>M<SMALL>ARC</SMALL> H. H<SMALL>EDRICK</SMALL>, M.D.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Attorney-in-fact</FONT></FONT></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-6 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>2
<FILENAME>d930893dex231.htm
<DESCRIPTION>EX-23.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-23.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 23.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>Consent of Independent Registered Public Accounting Firm </U></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We hereby consent to the incorporation by reference in the Prospectus constituting a part of this Registration Statement of our report dated March&nbsp;31,
2025, relating to the consolidated financial statements of Plus Therapeutics, Inc. (the Company) appearing in the Company&#146;s Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2024. Our report
contains an explanatory paragraph regarding the Company&#146;s ability to continue as a going concern. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We also consent to the reference to us under the
caption &#147;Experts&#148; in the Prospectus. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">/s/ BDO USA, P.C.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Austin, Texas</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">April&nbsp;23, 2025</TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-24.2
<SEQUENCE>3
<FILENAME>d930893dex242.htm
<DESCRIPTION>EX-24.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-24.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 24.2 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PLUS THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>POWER OF ATTORNEY </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The undersigned
director of Plus Therapeutics, Inc., a Delaware corporation (the &#147;Registrant&#148;), hereby constitutes and appoints&nbsp;Marc H. Hedrick, M.D., and Andrew Sims, and each of them, with full power of substitution and resubstitution and full
power to act without the other, his true and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">lawful&nbsp;attorney-in-fact&nbsp;and</FONT></FONT> agent to act in such director&#146;s name, place and stead, in any and all capacities,
to execute and file with the Securities and Exchange Commission under the Securities Act of 1933, as amended, or the Securities Act, this Registration Statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT> (File No. <FONT
STYLE="white-space:nowrap">333-286393)&nbsp;relating</FONT> to the offer and resale by certain selling stockholders of shares of common stock, par value $0.001 per share, of the Registrant, and any and all amendments, supplements and exhibits
thereto, <FONT STYLE="white-space:nowrap">including&nbsp;pre-effective&nbsp;and&nbsp;post-effective&nbsp;amendments</FONT> or supplements or any additional registration statement filed pursuant to Rule 462(b) promulgated under the Securities Act,
with full power and authority to do and perform any and all acts and things necessary, appropriate or desirable to be done in the premises, or in the name, place and stead of the undersigned, as fully to all intents and purposes as such person might
or could do in person, hereby ratifying and approving all that <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">said&nbsp;attorneys-in-fact&nbsp;or</FONT></FONT> any of them and any substitute therefor may lawfully do or cause to be
done by virtue thereof. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Signature</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Title</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Date</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">/s/ Kyle Guse</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Director</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">April&nbsp;23, 2025</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ALIGN="center"><B>K<SMALL>YLE</SMALL> G<SMALL>USE</SMALL> </B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g930893g25p25.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g930893g25p25.jpg
M_]C_X  02D9)1@ ! 0$ 9 !D  #_[1AV4&AO=&]S:&]P(#,N,  X0DE-! 0
M     "T< @   @  ' )0  ],97)O=7@L(%-P96YC97(< @4 #7!R:6YT;6=R
M(&9I;&4 .$))300E       0^%S$'QSQD,,]/QX[F=PR(CA"24T$.@
MY0   !     !       +<')I;G1/=71P=70    %     %!S=%-B;V]L 0
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M;VP      $-R;D-B;V]L      !#;G1#8F]O;       3&)L<V)O;VP
M $YG='9B;V]L      !%;6Q$8F]O;       26YT<F)O;VP      $)C:V=/
M8FIC     0       %)'0D,    #     %)D("!D;W5B0&_@
M1W)N(&1O=6) ;^            !";" @9&]U8D!OX            $)R9%15
M;G1&(U)L=                $)L9"!5;G1&(U)L=                %)S
M;'15;G1&(U!X;$!9%4B         "G9E8W1O<D1A=&%B;V]L 0    !09U!S
M96YU;0    !09U!S     %!G4$,     3&5F=%5N=$8C4FQT
M    5&]P(%5N=$8C4FQT                4V-L(%5N=$8C4')C0%D
M       08W)O<%=H96Y0<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M
M;&]N9P         ,8W)O<%)E8W1,969T;&]N9P         -8W)O<%)E8W12
M:6=H=&QO;F<         "V-R;W!296-T5&]P;&]N9P      .$))30/M
M   0 &15)0 !  $ 9%4E  $  3A"24T$)@      #@             _@
M.$))300-       $    6CA"24T$&0      !    !XX0DE- _,       D
M          $ .$))32<0       *  $          3A"24T#]0      2  O
M9F8  0!L9F8 !@       0 O9F8  0"AF9H !@       0 R     0!:
M!@       0 U     0 M    !@       3A"24T#^       <   ________
M_____________________P/H     /____________________________\#
MZ     #_____________________________ ^@     ________________
M_____________P/H   X0DE-! @      !     !   "0    D      .$))
M300>       $     #A"24T$&@     #00    8              %@   #]
M    !@!D ', <  P #  ,P    $                          0
M        _0   %@                      0
M   0     0       &YU;&P    "    !F)O=6YD<T]B:F,    !
M4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG          !"
M=&]M;&]N9P   %@     4F=H=&QO;F<   #]    !G-L:6-E<U9L3',    !
M3V)J8P    $       5S;&EC90   !(    '<VQI8V5)1&QO;F<
M!V=R;W5P241L;VYG          9O<FEG:6YE;G5M    #$53;&EC94]R:6=I
M;@    UA=71O1V5N97)A=&5D     %1Y<&5E;G5M    "D53;&EC951Y<&4
M    26UG(     9B;W5N9'-/8FIC     0       %)C=#$    $     %1O
M<"!L;VYG          !,969T;&]N9P          0G1O;6QO;F<   !8
M %)G:'1L;VYG    _0    -U<FQ415A4     0       &YU;&Q415A4
M 0       $US9V5415A4     0      !F%L=%1A9U1%6%0    !       .
M8V5L;%1E>'1)<TA434QB;V]L 0    AC96QL5&5X=%1%6%0    !       )
M:&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z06QI9VX    '9&5F875L=
M  EV97)T06QI9VYE;G5M    #T53;&EC959E<G1!;&EG;@    =D969A=6QT
M    "V)G0V]L;W)4>7!E96YU;0   !%%4VQI8V5"1T-O;&]R5'EP90    !.
M;VYE    "71O<$]U='-E=&QO;F<         "FQE9G1/=71S971L;VYG
M      QB;W1T;VU/=71S971L;VYG          MR:6=H=$]U='-E=&QO;F<
M     #A"24T$*       #     (_\        #A"24T$$0       0$ .$))
M3004       $     SA"24T$#      .!     $   "@    .    >   &D
M   -Z  8  '_V/_M  Q!9&]B95]#30 "_^X #D%D;V)E &2      ?_; (0
M# @(" D(# D)#!$+"@L1%0\,# \5&!,3%1,3&!$,# P,# P1# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# $-"PL-#@T0#@X0% X.#A04#@X.#A01# P,
M# P1$0P,# P,#!$,# P,# P,# P,# P,# P,# P,# P,# P,# P,_\  $0@
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M@&N)<2\_X'^4N5^M70\7HG4*<7&LLM;93ZKG6EI,[G,AOILK]NUJ<*M&KJ]
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M=HYCA^8Y7EQOU*<X9>8P?0-;'.^(<YK?^_+LE8PS,\8D=RUL^,8\DHC8;/\
M_]'U5><_XR#_ );Q>?Z+V!_TCUZ,DD%.#]1__$M@_"SD1_A;?%;R94,OZP=$
MP<AV-F9U-%[0'.J>\!P:=0XM24Z"%D?T>W^H[\A5<=9Z4[%HS!EU'&RGBK'N
M#AL>]Q+&UUN_.?O8YJ,,W#=F.P1:PY;&"UU$C>&$[&V;?W=Z14^98UUM!JNI
M<YEM8!8\ R#'F%=_;W6O^YEWW#_R"[-_UG^KM=QQW]1QV7-?Z9K-C0=X=Z>R
M/WMZ-G];Z1TZQM6?F4XKWMW-;:\-)$[=WN_E*H.4(VR2'E_Z,W3SL3K+#&1[
MG_T5X?\ ;W6O^YMWW#_TFNM^JN5DY?2O6RK'76>J]N]P@P#[1H&K4HR<?)I9
M?CV-NIM$UV5D.:X>+7M]J'BY^#ENN;BW,N=CV&F\,()8]OTJWQ^<I<6&4)69
MF>FQ8<V>.2-#'&&MW%Y[ZR?5VZZ]W4,!N][_ .?H$ DC_#5?O/V_SE:Y_&ZI
MU/I9--%[\;4DTO @'O\ HKFG9_87<Y77^A8F2<3+SJ*,@;9JL>UKAN]S/I?O
M(G4.H=)PZ66]1NIIJ>=K'7$!I,;_ &[OY(39\M<N.$C"1WI?CYLB(A.(R1&U
MO!Y/5>I]3BBZ]^2"=*:P()\ZJ&_I/[2WOJY]7;J+V9^>W8]G]'H,$@G_  ML
M>W?M_FV+;PNK=$R,:[)PLFBS'Q@3?94YNU@#?4/J;?H_H_>BGJ736LQ7F^L,
MSB!B&1%I</48*OW]S/<ECY:I<<Y&<AM:LG-DQ,(0&.)WK=-<S?6ZO<YF\%N]
MAAPD1N8[]Y<+U'ZL=1P7%U3'9= ,MNK!-@/[UM8_2>I_PE2ZW*^L70<2^S&R
ML^BF^J/4K>\!S9 >-S?ZCD?]J=,]+&O^T5>EFN:S%LW#;8Y^M;:G?GN<I,N&
M.0"[!&Q#%ASSQ$F-$'<%X6KZR=9QV^G]K)V]KFM<X?VK!ZG^<Y0LR>K=9N:T
MFS,>WZ#&-&QL_P!3;4S^O8N[ZCG=)P:A=U*VFBLF&NN+1)\&[_I*=&?TZS#^
MV49%+L-H+C>US?3 &KBZP'8S;^<H?NLCZ999&/9G'-P'JCAB)]VC]7>BGIF(
M[UB#E7D.NVZ@1]"IO]25L*GT_J_2NI-<[I^55E!FC_2<'$3QN:WW-5Q68Q$0
M(C8-64C*1E+4E__2]527RJDDI^JES7UQPZGCIMK,<66NZEBMM>*]SC6'.W"P
MAKG.I_K^Q?/222GZ#^N6*1TWI^/AU^EMZCC^GZ5>X5R7_I?18-NUC_>A=&Q.
MI8WUQRFY^0[.L.!7^M>B*6G]+I5MKW5;V?UUX"DBI]CZ?8,?J>0<BY]+/VE:
MXXQZ:[)]1AN_-S=GZ%MO_@7\ZM?ZPX_4K?K52[IV/3?<WI]A#<JLOI=%L^F'
MMVMKR'_X/>]>"I)*?>.BY8Z1]2KLS'9;9EN?:\XYI+',RK7;?L[,0#VTTV.;
M_8_2*M]7L3J?U?ZMBTY>&:,?J%(Q;[6/-X?E5[KZ\N_8S] ^[U+*MCO9_P (
MO$$DE/N74.E]3ZC]8NN8V'7B^GD4XS++<VI[P&NK<S?A[!Z?JL]^[W?Z)%^M
M6"[!Z1T/$KLL<W"R*V')]$WEH938SUWXS0_U/^*7A"22GW_I33F_5SJN)1:<
MK)M9;6'G#^P FRK;55Z4-;9_QRS\7)?U,_5KI^/BY#,CI3ZWY_K5/K;4*:C0
M\/LL;L<ZQ_\ -;%X@DDI^@_K1A5.ZKT-[<=KS;G 9#Q6'2T5N'Z=S6_0_P",
M4_K/1M=T*NBHBNOJ='MK;[6M ?\ FL&VMC5\\I)*??>NMJP_K51U7J>*_*Z9
M]D---K*C<VB_?O>ZREF_;ZU9]MFQ%S6]+S_JCEMIZ=EXF#:2?L]&.&7N/J-L
M^TU8OY];W_IO?_.4KY]224^^?5')RK<_,80W+QO3K(ZH,,X5CWCV_9+6.:SU
MO29_VVNN7RJDD5/_V3A"24T$(0      5P    $!    #P!! &0 ;P!B &4
M( !0 &@ ;P!T &\ <P!H &\ <    !0 00!D &\ 8@!E "  4 !H &\ = !O
M ', : !O '  (  R #  ,@ Q     0 X0DE-!"(      4Y-30 J    "  (
M 1(  P    $  0   1H !0    $   !N 1L !0    $   !V 2@  P    $
M @   3$  @   !\   !^ 3(  @   !0   "= 3L  @   !    "QAVD !
M  $   #$    \    &0    !    9     %!9&]B92!0:&]T;W-H;W @,C(N
M," H5VEN9&]W<RD ,C R-3HP-#HP,R Q,CHQ,CHS. !,97)O=7@L(%-P96YC
M97(       .@ 0 #     ?__  "@ @ $     0   /V@ P $     0   %@
M        !@$#  ,    !  8   $:  4    !   !/@$;  4    !   !1@$H
M  ,    !  (   (!  0    !   !3@("  0    !              !(
M 0   $@    !.$))30/]       (          #_X0%617AI9@  34T *@
M  @ " $2  ,    !  $   $:  4    !    ;@$;  4    !    =@$H  ,
M   !  (   $Q  (    ?    ?@$R  (    4    G0$[  (    0    L8=I
M  0    !    Q    /    !D     0   &0    !061O8F4@4&AO=&]S:&]P
M(#(R+C @*%=I;F1O=W,I #(P,C4Z,#0Z,#,@,3(Z,3(Z,S@ 3&5R;W5X+"!3
M<&5N8V5R       #H $  P    '__P  H ( !     $   #]H , !     $
M  !8          8! P #     0 &   !&@ %     0   3X!&P %     0
M 48!*  #     0 "   " 0 $     0   4X" @ $     0
M2     $   !(     ?_A/QMH='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O
M #P_>'!A8VME="!B96=I;CTB[[N_(B!I9#TB5S5-,$UP0V5H:4AZ<F53>DY4
M8WIK8SED(C\^"CQX.GAM<&UE=&$@>&UL;G,Z>#TB861O8F4Z;G,Z;65T82\B
M('@Z>&UP=&L](D%D;V)E(%A-4"!#;W)E(#8N,"UC,# R(#<Y+C$V-#0X."P@
M,C R,"\P-R\Q,"TR,CHP-CHU,R @(" @(" @(CX*(" @/')D9CI21$8@>&UL
M;G,Z<F1F/2)H='1P.B\O=W=W+G<S+F]R9R\Q.3DY+S R+S(R+7)D9BUS>6YT
M87@M;G,C(CX*(" @(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](B(*
M(" @(" @(" @(" @>&UL;G,Z>&UP/2)H='1P.B\O;G,N861O8F4N8V]M+WAA
M<"\Q+C O(@H@(" @(" @(" @("!X;6QN<SIP9&8](FAT=' Z+R]N<RYA9&]B
M92YC;VTO<&1F+S$N,R\B"B @(" @(" @(" @('AM;&YS.F1C/2)H='1P.B\O
M<'5R;"YO<F<O9&,O96QE;65N=',O,2XQ+R(*(" @(" @(" @(" @>&UL;G,Z
M>&UP34T](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]M;2\B"B @(" @
M(" @(" @('AM;&YS.G-T179T/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q
M+C O<U1Y<&4O4F5S;W5R8V5%=F5N=",B"B @(" @(" @(" @('AM;&YS.G-T
M4F5F/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O<U1Y<&4O4F5S;W5R
M8V52968C(@H@(" @(" @(" @("!X;6QN<SIP:&]T;W-H;W ](FAT=' Z+R]N
M<RYA9&]B92YC;VTO<&AO=&]S:&]P+S$N,"\B/@H@(" @(" @(" \>&UP.D-R
M96%T941A=&4^,C R-2TP-"TP,U0Q,CHQ,3HS,"LP-3HS,#PO>&UP.D-R96%T
M941A=&4^"B @(" @(" @(#QX;7 Z0W)E871O<E1O;VP^36EC<F]S;V9TPJX@
M5V]R9" R,#$V/"]X;7 Z0W)E871O<E1O;VP^"B @(" @(" @(#QX;7 Z36]D
M:69Y1&%T93XR,#(U+3 T+3 S5#$R.C$R.C,X*S U.C,P/"]X;7 Z36]D:69Y
M1&%T93X*(" @(" @(" @/'AM<#I-971A9&%T841A=&4^,C R-2TP-"TP,U0Q
M,CHQ,CHS."LP-3HS,#PO>&UP.DUE=&%D871A1&%T93X*(" @(" @(" @/'!D
M9CI0<F]D=6-E<CY-:6-R;W-O9G3"KB!7;W)D(#(P,38\+W!D9CI0<F]D=6-E
M<CX*(" @(" @(" @/&1C.F-R96%T;W(^"B @(" @(" @(" @(#QR9&8Z4V5Q
M/@H@(" @(" @(" @(" @(" \<F1F.FQI/DQE<F]U>"P@4W!E;F-E<CPO<F1F
M.FQI/@H@(" @(" @(" @(" \+W)D9CI397$^"B @(" @(" @(#PO9&,Z8W)E
M871O<CX*(" @(" @(" @/&1C.G1I=&QE/@H@(" @(" @(" @(" \<F1F.D%L
M=#X*(" @(" @(" @(" @(" @/')D9CIL:2!X;6PZ;&%N9STB>"UD969A=6QT
M(CYP<FEN=&UG<B!F:6QE/"]R9&8Z;&D^"B @(" @(" @(" @(#PO<F1F.D%L
M=#X*(" @(" @(" @/"]D8SIT:71L93X*(" @(" @(" @/&1C.F9O<FUA=#YI
M;6%G92]E<'-F/"]D8SIF;W)M870^"B @(" @(" @(#QX;7!-33I);G-T86YC
M94E$/GAM<"YI:60Z-S5B,3!B9&0M-#(X-RTQ,C1C+3DS8F(M968W,6-E.64V
M8C W/"]X;7!-33I);G-T86YC94E$/@H@(" @(" @(" \>&UP34TZ1&]C=6UE
M;G1)1#YA9&]B93ID;V-I9#IP:&]T;W-H;W Z,S0X,6%E-&0M-S8S-"TW9C1C
M+6$U93<M934T,31F,S$V-V$X/"]X;7!-33I$;V-U;65N=$E$/@H@(" @(" @
M(" \>&UP34TZ3W)I9VEN86Q$;V-U;65N=$E$/GAM<"YD:60Z,&)C.69A.# M
M,S5C,RTQ831C+6$W86,M961C93 Y.6,V.&4Y/"]X;7!-33I/<FEG:6YA;$1O
M8W5M96YT240^"B @(" @(" @(#QX;7!-33I(:7-T;W)Y/@H@(" @(" @(" @
M(" \<F1F.E-E<3X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54
M>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IA8W1I
M;VX^<V%V960\+W-T179T.F%C=&EO;CX*(" @(" @(" @(" @(" @(" @/'-T
M179T.FEN<W1A;F-E240^>&UP+FEI9#HP8F,Y9F$X,"TS-6,S+3%A-&,M83=A
M8RUE9&-E,#DY8S8X93D\+W-T179T.FEN<W1A;F-E240^"B @(" @(" @(" @
M(" @(" @(#QS=$5V=#IW:&5N/C(P,C4M,#0M,#-4,3(Z,3(Z,CDK,#4Z,S \
M+W-T179T.G=H96X^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IS;V9T=V%R
M94%G96YT/D%D;V)E(%!H;W1O<VAO<" R,BXP("A7:6YD;W=S*3PO<W1%=G0Z
M<V]F='=A<F5!9V5N=#X*(" @(" @(" @(" @(" @(" @/'-T179T.F-H86YG
M960^+SPO<W1%=G0Z8VAA;F=E9#X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^
M"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R
M8V4B/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N/G-A=F5D/"]S
M=$5V=#IA8W1I;VX^"B @(" @(" @(" @(" @(" @(#QS=$5V=#II;G-T86YC
M94E$/GAM<"YI:60Z-#@Q8S=E83(M9&4T82UA.#0X+6$Y9#<M8S0W861C8C!C
M,65D/"]S=$5V=#II;G-T86YC94E$/@H@(" @(" @(" @(" @(" @(" \<W1%
M=G0Z=VAE;CXR,#(U+3 T+3 S5#$R.C$R.C,X*S U.C,P/"]S=$5V=#IW:&5N
M/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z<V]F='=A<F5!9V5N=#Y!9&]B
M92!0:&]T;W-H;W @,C(N," H5VEN9&]W<RD\+W-T179T.G-O9G1W87)E06=E
M;G0^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IC:&%N9V5D/B\\+W-T179T
M.F-H86YG960^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @
M(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @
M(" @(" @(" @(" @/'-T179T.F%C=&EO;CYC;VYV97)T960\+W-T179T.F%C
M=&EO;CX*(" @(" @(" @(" @(" @(" @/'-T179T.G!A<F%M971E<G,^9G)O
M;2!A<'!L:6-A=&EO;B]V;F0N861O8F4N<&AO=&]S:&]P('1O(&EM86=E+V5P
M<V8\+W-T179T.G!A<F%M971E<G,^"B @(" @(" @(" @(" @(#PO<F1F.FQI
M/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U
M<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T179T.F%C=&EO;CYD97)I=F5D
M/"]S=$5V=#IA8W1I;VX^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IP87)A
M;65T97)S/F-O;G9E<G1E9"!F<F]M(&%P<&QI8V%T:6]N+W9N9"YA9&]B92YP
M:&]T;W-H;W @=&\@:6UA9V4O97!S9CPO<W1%=G0Z<&%R86UE=&5R<SX*(" @
M(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(#QR9&8Z;&D@
M<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \
M<W1%=G0Z86-T:6]N/G-A=F5D/"]S=$5V=#IA8W1I;VX^"B @(" @(" @(" @
M(" @(" @(#QS=$5V=#II;G-T86YC94E$/GAM<"YI:60Z-S5B,3!B9&0M-#(X
M-RTQ,C1C+3DS8F(M968W,6-E.64V8C W/"]S=$5V=#II;G-T86YC94E$/@H@
M(" @(" @(" @(" @(" @(" \<W1%=G0Z=VAE;CXR,#(U+3 T+3 S5#$R.C$R
M.C,X*S U.C,P/"]S=$5V=#IW:&5N/@H@(" @(" @(" @(" @(" @(" \<W1%
M=G0Z<V]F='=A<F5!9V5N=#Y!9&]B92!0:&]T;W-H;W @,C(N," H5VEN9&]W
M<RD\+W-T179T.G-O9G1W87)E06=E;G0^"B @(" @(" @(" @(" @(" @(#QS
M=$5V=#IC:&%N9V5D/B\\+W-T179T.F-H86YG960^"B @(" @(" @(" @(" @
M(#PO<F1F.FQI/@H@(" @(" @(" @(" \+W)D9CI397$^"B @(" @(" @(#PO
M>&UP34TZ2&ES=&]R>3X*(" @(" @(" @/'AM<$U-.D1E<FEV961&<F]M(')D
M9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @/'-T4F5F.FEN
M<W1A;F-E240^>&UP+FEI9#HT.#%C-V5A,BUD931A+6$X-#@M83ED-RUC-#=A
M9&-B,&,Q960\+W-T4F5F.FEN<W1A;F-E240^"B @(" @(" @(" @(#QS=%)E
M9CID;V-U;65N=$E$/GAM<"YD:60Z,&)C.69A.# M,S5C,RTQ831C+6$W86,M
M961C93 Y.6,V.&4Y/"]S=%)E9CID;V-U;65N=$E$/@H@(" @(" @(" @(" \
M<W12968Z;W)I9VEN86Q$;V-U;65N=$E$/GAM<"YD:60Z,&)C.69A.# M,S5C
M,RTQ831C+6$W86,M961C93 Y.6,V.&4Y/"]S=%)E9CIO<FEG:6YA;$1O8W5M
M96YT240^"B @(" @(" @(#PO>&UP34TZ1&5R:79E9$9R;VT^"B @(" @(" @
M(#QP:&]T;W-H;W Z0V]L;W)-;V1E/C0\+W!H;W1O<VAO<#I#;VQO<DUO9&4^
M"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" \+W)D9CI21$8^"CPO>#IX
M;7!M971A/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @( H\/WAP
M86-K970@96YD/2)W(C\^_]L 0P &! 4&!00&!@4&!P<&" H0"@H)"0H4#@\,
M$!<4&!@7%!86&ATE'QH;(QP6%B L(",F)RDJ*1D?+3 M*# E*"DH_]L 0P$'
M!P<*" H3"@H3*!H6&B@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H_\  $0@!!P+U P$B  (1 0,1 ?_$ !P   $$
M P$                ! @8' P4(!/_$ %00  $# @,$!00*#P<$ @(#  $
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MXG@E:!;M"RP1QLD!<'@$>"OG:#9FDQ2F);!&UQ(S<3R5+XYA,N%U1;D&DDY
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MXAGH4F9JHQL&/_P-'\0ST*3QC-=1;]"./N?B,<=4!!U0%ZK<\6*A"%(!"$(
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M4V,*S4D?25$;!F25B=I_-;79>G-3CU#%PDATEM+\DMUZE]"DNF7R+MV$BZ+
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MAH/%V88W:&W-0"Z[B]KBZ+CO5<[J]KY=J#,^=\K_ &(/Z\;&ZFWN589MV $
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M(;+$YS7]*&W:T.U!//S* 2.X[T*@,)WLUU3C,-&^HJ2R1Q!'01 9 \]>2N[
M:LUV&P3.)/'&UV8 U'@@-B"#H0A8RT,S&BR6YH R"0D-%R0!XJ#[7[>46#F6
M(QU?31%[>)C&$7'G<JMK=[N(U,SFP550V+(@.IXD!T6,]$+G.@WR8B^=K'U5
M26WL?O>%63LAO$IL4'1U#:M\EF"YC8!<^8H"PT76&GG9,P&,. \5D( ZHU*
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M -H:;R.D;&V^1/:-^:P8_,Z'":B46XFM%KZ:A; Y-N3Q+QXI3>78;/"#P\8
MO:_.^B(DY,VWQ(8MM-5T\Q:."I>WJ @YFW-6!L%NWI<3P2FJ@^L+I&O[,C ,
MGD<V^"@^WN!56$[1XG.ZEG<QU1(YLAA+0;&]P5EV:V^Q'"J**GA%9PL#@ VJ
M<T9NOI9222G:G='614TCJ*"JD(:VW%/%KQ?)R4BW1; 5&$SS3UL4\3@Z!X!E
M8X7;Q$Z)F"[XJ>H]@K\/B:'./6FK0;"WBWO"LS9O',,Q>%LF'U='Q<+'/C@F
M:\@NT!M\J WC'!CBR^00R[7AH[)YIL\9=FTD&^H"=&X%UFV>/?#DH!E0A"@
MA"$ (0A "$(0 A"$ (0A "$(0 A"$ (0A "$(0 FNR:>%.3)22P\.: 0DAO6
M[ERKO=?!]N.)\3'$^4N] \5U6TG@/'D++E/?"*?[<,2)D=Q>4NY> \%*!9NX
M/A=@\.7NY?2K?!#@0 J@W 2,^PD(XL^.7EXA6X8\[MS4L@4\3="O#BS;TY<_
M,7"]X)X;+78ZWBPL\>76&BJ#D+&HA-CT_1V!$SQG\(JQ-G=UM3CF$4U4'45I
M&<?7ED!_@%76(L@BQ2LL]W$9GD _"/@NG=U;Y/M*PCHV@_>XU\Y5D"MQN7JH
MY^DXL/TM[?+_ ,56>UF"_8:M;'+T9[78<3H;<UV,#+;-HNN4=[;F.QEHF/#[
M9I\)3 %E;@.%\4Y:+ 4S3G\)7$QP<;E4S_\ Q\=&V*7HW$_>S=?A*YWNM);P
M42!%MYS2[8O% />-]=JY8CII9\<-.QS1TTXCSTS=9=4;T(FG8?%7$F_ SUVK
ME.FFCI<?,Y=G#4!XN+C)UU, 6K0[G*FOI&R.=AYN3K-*-#X-7H.Y2JFIWL+L
M.[LYY?\ BDP[?!Y% V,NHA:^L$IY^!7M&^EL4;B7T/?^#S?6C*HF6[C8RKV4
M9,UTE-PO8QA$3W.R;?WP\5.7 $=7)5'LYO7&*XE# 'T9Z65C.K#*#UG6YE6Z
MYUV]3-4+H\>-!_V+GX2-!Z0N3-MHG':?%;D<7E#_ $KK+&@Y^%SAPY#3SKD?
M;2-C-LJXN)%JQWK*\2&8J/#J]] V2GFA;<D9^?S+6F:9S^AK'B1[M"T "W\%
MTSNBAICLE2U)D?UG2-\.V?!0[?=L<Z1[:^E;,]D5.+DR, !+SRUYJS8(=NUV
M*=M'B#W2^3NAIW1OX7R/:;%W*P\%TI@>%T^!X<REIHPQC2;!KB[4WYKE;8;:
M*3 \8CB(A#>EC9(7M<2 '9Z%=28%B%)CE$R>GEXPXGLM+=#;F%1@V36F$$-(
M U6GVQKV8;L]B$H#Q*ZEE<TM -B&'O\ .MU(PND#CH J1W\;2TXCIJ/I&7#:
MF$C@=?W(UT5, I_::LFK<5GK7ONZ0M!) !R:!H,N2F.S6\6IV;HGTT4T[0Z0
MRV9#&X9@#W7F6JW;;)Q[4UTD0,Y @=+[&]K='AONAXJRX]S-)-&3*_$&NO:P
MFBT^:K%2J-J]I),>G$\CY'.+GO!>QK<W$'DMUNJQ\X!BLM43)Q/IG1$L:UQS
M>T\_,IMB6YZGI\.JI837N?%$YS0Z:*Q(!(OU?!4[54PPK'ZJEJ[Q]&T:GB-R
M&GEYT+([09PRQ.#1E?F@,Z-CR>S;.W<H9NWQZ'',%GEIGL>X5#F -8YHR:T\
M_.IL >C;Q9$! 5-OYF@=LS3-#'95K/\ ZY/%<_4LTC90('<)\0NA]^KB_9Z!
MO=6,/_ZWJG-T_!4;24<;R1Q/DT^+*N5P:=]3BKVF..JC'%D+M'U+TX;LMB6+
M2-\HGI7C)V;BWG;DU=84-!3QT-/UY.M&V^G=YEZXJ6&(<3'//G__ ,5<C!"-
MW&Q4>!0M>YD/$U[SU)'G4 <U/00X\+?<Y)[3TC;IC0(@X@]8Z J"<$?VV)&%
M%K\QGZI7)6%4QEJVTL=AQ NS.6BZQV] ."M=(;$N.GP2N2Z)T%+4BJ#S=H(S
M&6:E$LMO#]RU754<-0UV' 3,;)G/+?,7][XK++N1K; <>&V!_/R_\4ZBWPFB
MP^D@C=0D1Q-9UH);Y #O7J9OJ(;Q/=0"_P#V\OUJVI4F6[O8RHV=HPQSJ;*1
MSO8WN=J .8\%/0"WA#LRJAV7WJMQK%(Z?CI"'!W8AE!R%^95LL>)::*<>\#O
M#2ZHRZ-?M 87TD['L<7-:3_ KCIKW-=PR&[>X+M*>G;4TSW.+KN:=%RAO!V=
MJ:'% #$\1]$TDE[2=3W*$0SIK8YS9L&@#00T1L!!^"%L:R.H$4O1R-$;6DV/
M=;S+F[8C>2W!6&*5]*U@<+ET4CB+"W(K>X_O;$]*\4SZ-[90X7,$HR(\2KE2
M'[W*IC]K)39W'T4>?R*V]P$+G8/7R2$$MF9;YJY^I89\:Q;IFL!<66ZI &7G
M74V[C WX7AMY6O:7\#A=S3[GP5&71-$("%"!I-MQ?9/$P->B/I7)&(-D&T\@
M#A[>WTA=:[<@.V2Q0.T,)]*Y%KA&S:B3K'V]OI"L@=7;N&$;.,)M?I'^E28G
M._<HQNZ:V39IA!/MK_2I/<,RY\D K#=Q40WHM<=GF6(_"&>ARF#"3KHH9O08
MTX VY/M[?0Y$#F3 (Y?MDIKN:6\;O05UILD_BV=PUA]S P?P7(^!EL>TM,X'
M,.=KYBNN]DB#LOAKN^F8?X*6#9R-:6\-LKW7-F_:AD9C]&82QOWKWGW[ETI$
M YO$H%O7V<.,X/4RP"5\K(FL :]K0>O?GYU'<@JG<?BII,3JHIR]Q)A8.%H]
M\5T<QXE/21@AQRN5Q?)25.SF,2.DC#3TWNR'=D_JE6?LMO4DP^G8Q_D0 #M8
M9#J? J[1!T% \N:[B-W7R2L?=[FF^1LJ"VBWNU-?A\U-&V@+9&@$B&0'6_-R
MC6Q>UF*SX\6MIZ0QF://A=IQ?"523J.69C#PN#C;N61HMV<@M=A%:9:)CJCA
M:\DW#0>]8MI<0DH,'J:RG#'.B:".,&VH'@H)/'M)LQA6.0R1UE+TDA#@"9'M
M%R/ JL\7W,5$DCG8,</IV$BPDGE.5L_<GFH!CVV-?'M2ZJZ*ERJ^D[+K9.O[
MY3G"M\D<-)'%B,E%%P@]F"4YW/<3R5D05UM+L75;/W?B+Z:7A8'>PO<<B;#4
M#FO3NOQZJPK:&&G@E<R*JJH&%H8TY!Y%C?X2D.WF\N+'\!JL,BDIG4\X9Q.9
M#(UP+7AV5\N0Y*+[N:*IK=I</=%'Q10U<!+@X#+CUS/@I8.L,/G,U)'(XDDW
MSMXI\+6PGHP,SGDL-!#T436F]P#Z5DA;TKQ,_)S<@!I__<UY@]"$(0D$(0@!
M"$( 0A" $(0@!"$( 0A" $(0@!"$( 0A" $T9--\T(0&)S^,\(RY*C=N=B8\
M4VEQ&=]6UGLQ?PF#B_W(0I1!-MUF ,PW"8^CF:;.?V8^'4^=6!&+--\T(4L(
M7*Q-M%XZZ#R^A,8=T5W WM?1"%4% 5.[(5.*32?94-O*XV\FOS/ZZNC8S!G8
M/@%%3"J,H9$& AG#S/*Y0A2#?\#K\/2'SJDMN-WK<6Q 2NQ!K".+(T_%JZ_O
MD(4P!*MU.S3<",S!4":T(;<1<&A\Y5C !XO8 H0HEN"/;98<[$MFJ^G-08P\
M 7X>*W6!TNJ0?NO;)432_94"[N*WDO\ [(0K0(&?<N9)G]E&C_XO_LFR;K6O
MZOV5%O\ *_\ NA"ED(WFRF[9N'8I1SC$P_HYHW\(IN&]G V[2OK(-T"$+S+G
MEK(#5TDL8D+.+*]K\U0V/[NA7;1XA,[$PWV=S[&GOS^$A"O$AEM;O,%;A>R]
M/2]*)0USS?@X=7$Z7*VF,T$.-834TTK(V\8#>)S ^V8.B$*.X*.V@W6,@Q*:
M>+%&LXY'. ;2VMG\)6'NLPF?#8.@?B$M0UL;]00,W@Z7*$(P3V;B= YH<0>]
M4;MIL5]F\9DDFQ"PCGE<&OAX^T[3M>"$*.Y!-=UFR<&  31R12.="^/JP!AS
M>#K<]RGTI(/"TVN-0A"DA#)HN.!T;C<2-+3<7U"IK>+NY@KL3GK(ZR*!TCV"
MS:4$BS+:\0[D(4%C>[I]GW[/<-+Y:ZH8^=\IZG ,XP+6N>Y68"7%V9 ;R[T(
M0DA6\K!!C.%QLZ?H1Y0U_8XM&.'>.]5_L%NV^QFTM',W%N/A+SPBGX;W8X>^
M0A6(1>4<0@IX83URUH9Q$=PM=9F@", @%"%4"1D!N0 32RYXB=,[(0@1J=H,
M,^R](^'INB#;N[/%R(TN.]4$S=:)*<C[+ 9_HO\ [H0I08HW5M##?%@;?]K_
M .ZS/W5L-+&?LHW/_M/_ '0A7*FWV)W=,P[&X9&X@U]@[(4W#JT_K*\*2(PT
MT<9=QAK0W/G8(0J,NC+QBW"&V'@HQMCLG1XU2R.+*>*0AK>,TX<18W\$(540
M4UC^ZR&DDLS$(^N"[*D Y_"7BH-W,=2]D)Q!H#2!<TU^?PD(5RJ+5V-W:4.$
M%LDDE-5$<0LZC:-?E*L&**Q9T9Z-C,N%HL"A"HRZ/2A"%"!K-IJ/R_ :ZEZ3
MH^ECX>.U[?(J&EW:-?C4DKL3:3T@=G3>/PD(5D"[]E*#[%8.V$2=* ]Q[/#K
M\I6Z:X/%RT9(0A CGV! "CFV6%.Q'"6L-06#I6N[/%H#XH0H1)3>";NF1XO%
M5.Q!KPQQZAIM<CSXO%7S@M-Y-@])"U]VLB:T6%M!W(0K,'N:WAB !YIDL3'1
MN9(ULC#JUPN"A"J00/:S=M0XWTD[9*:G(+Y,J1KM?&X548SNT;3S.9'B8:!;
MLTUN7PD(5T0+A6Z[RBMBC=B^3CSIK\OAJU]DMVU!@C6S/=2U+[,-S1M:;C.]
M[E"%#+$[@9%PV9"QH[@ BHIXIJ=\,\4<L3NTQ[00?."A"@%>[8;L</QB*22G
M=24+R'NXHZ)I-R,LP1HJIQ3=DW"IG]+BC:H7#;.IK:B]^T4(5HD'HP+=I'B5
M;&[[(,C9<M+/)00;"]^TK@V&V,H<$:\AM--(.CL\4S6D%M\]2A"E[!$Q)Z.5
;QU&EDX-X7@#(=P0A>8,B$(0D$(0@!"$(#__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
